<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01648140</url>
  </required_header>
  <id_info>
    <org_study_id>115879</org_study_id>
    <nct_id>NCT01648140</nct_id>
  </id_info>
  <brief_title>Dose Ranging of GSK2336805 in Combination Therapy</brief_title>
  <acronym>HAI115879</acronym>
  <official_title>A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK2336805 is a novel hepatitis C virus (HCV) non-structural 5A (NS5A) inhibitor being
      developed for the treatment of chronic HCV infection. This Phase II, multicenter,
      parallel-group, randomized, dose-ranging study will assess the safety and tolerability,
      antiviral activity, and pharmacokinetics of GSK2336805 at 2 dose levels (40 and 60 mg) in
      combination with pegylated interferon alfa-2a (PEG) and ribavirin (RIBA) in approximately 100
      treatment-naïve subjects with chronic genotype 1 HCV infection.

      In a separate nonrandomized single-arm cohort, up to 15 treatment-naïve subjects with
      genotype 4 chronic HCV infection will be enrolled in parallel at the dose level of 60 mg of
      GSK2336805.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with chronic genotype 1 hepatitis C virus (HCV) infection will be randomly assigned
      on a 2:2:1 basis to 1 of 3 treatment arms: T40 (GSK2336805 40 mg and PEG + RIBA) or T60
      (GSK2336805 60 mg and PEG + RIBA) or PEG + RIBA and telaprevir (PRT). Randomization will be
      stratified by interleukin 28B (IL28B) rs12979860 status (C/C versus carriage of the T
      allele), HCV genotype (1a vs. 1b), and plasma HCV Ribonucleic Acid (RNA) (&lt;800,000 IU/mL
      versus ≥800,000 IU/mL).

      An additional nonrandomized single-arm cohort of subjects with chronic genotype 4 HCV
      infection will be enrolled in parallel. A maximum of 15 genotype 4 subjects will receive
      GSK2336805 60 mg and PEG + RIBA. The purpose of this cohort is to further characterize the
      antiviral activity of GSK2336805 in subjects with chronic genotype 4 HCV infection. The
      schedule of assessments for the genotype 4 subjects will be the same as for the genotype 1
      subjects. Recruitment of the genotype 4 subjects may be terminated when the target sample of
      genotype 1 subjects have been randomized.

      Subjects in a GSK2336805 treatment arm who achieve extended rapid virologic response (eRVR)
      will receive a total of 24 weeks of therapy (12 weeks GSK2336805 in combination with PEG +
      RIBA followed by 12 weeks PEG + RIBA). Subjects who are HCV detectable at Week 4 and then
      undetectable at Week 12 will receive a total of 48 weeks of therapy (12 weeks GSK2336805 in
      combination with PEG + RIBA followed by 36 weeks PEG + RIBA). Subjects in the telaprevir
      treatment control arm will be managed according to the current product label for
      treatment-naïve subjects.

      Subjects who complete treatment will undergo follow-up monitoring for 24 weeks after
      completion of therapy. At the end of the 24-week follow-up visit, subjects will have
      completed their participation in the study. The total duration of the study will be 48 weeks
      for subjects who achieve eRVR at Week 12 and up to 72 weeks for subjects who do not achieve
      eRVR at Week 12.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1, 2012</start_date>
  <completion_date type="Actual">July 16, 2014</completion_date>
  <primary_completion_date type="Actual">July 1, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving eRVR</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>eRVR is defined as plasma HCV ribonucleic acid (RNA) &lt;lower limit of quantification (LLOQ) and target not detected at Weeks 4 and 12. Participants who discontinued prior to Week 12 assessments or had missing HCV RNA values at Weeks 4 and 12 were treated as non-responders.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12</measure>
    <time_frame>From the start of study treatment up to Week 12</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) up to 12-week treatment period</time_frame>
    <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24. Change from Baseline in SBP and DBP is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Day 2, Weeks 1, 2, 4, 6, 8, and 12</time_frame>
    <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4, 12 and 24. Change from Baseline in heart rate is summarized for each post-Baseline assessment upto Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils, platelet count and white blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of hemoglobin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of hematocrit at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of albumin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4 Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin and creatinine at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
    <description>Blood samples were collected for the measurement of Creatinine Clearance at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. It is estimated by Cockcroft-Gault Equation. Change from Baseline in the Creatinine Clearance values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12</measure>
    <time_frame>Baseline (Week 0), Weeks 2 and 12</time_frame>
    <description>Urine samples were collected for urinalysis at Baseline, Weeks 2, 12, 18, 24, 48 and PT FU Weeks 4. Number of participants with shift from Baseline in urinalysis to normal (NL), abnormal (ANL) and missing (MIS) data up to Week 12 are summarized. Urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine leukocyte esterase test (ULET) for detecting WBC, urine nitrite (UNIT), urine occult blood (UOB) were performed with dipstick method. Urine microscopy (UM) is performed to detect bacteria (BAC), red blood cells (RBC) and white blood cells (WBC). Other urinalysis parameter included urine pH (UpH) and urine specific gravity (USG). Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1 and 12</time_frame>
    <description>The ECG parameter heart rate was measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 1 and 12</time_frame>
    <description>The ECG parameters including PR interval, QRS duration, uncorrected QT interval, QTcB, QTcF were measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG parameters are summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any AEs and Any SAEs After Week 12</measure>
    <time_frame>From Week 12 up to PT Week 24 FU</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT)</measure>
    <time_frame>From the start of the treatment up to PT FU Week 24</time_frame>
    <description>Blood samples for the determination of HCV RNA levels were collected at Screening and Baseline, every study visit during the Treatment Period, and at PT FU Weeks 4, 12, and 24. vRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 2 weeks after initiation of therapy. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. cEVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after initiation of therapy. SVR12 is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after completion of all therapy. SVR24 is defined as plasma HCV RNA &lt;LLOQ and target not detected 24 weeks after completion of all therapy. SVR24 with RGT are participants who achieved both SVR24 and eRVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12</measure>
    <time_frame>Day 1, Day 2, Week 4, and Week 12</time_frame>
    <description>Plasma pharmacokinetic (PK) samples were collected for all participants on Day 1 (0 hour [h]-1h, 1h-4h, 4h-8h, 8h-20h), Day 2 (Predose [20-28h]), Week 4 (Predose [20-28h], 0h-1h, 1h-4h, 4h-8h, 8h-20h, 20h-28h) and Week 12 (Predose [20-28h]). PK Population is comprised of all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4</measure>
    <time_frame>Week 4 (24 h post dose)</time_frame>
    <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximal Plasma Concentration (Tmax) of GSK2336805 at Week 4</measure>
    <time_frame>Week 4 (24 h post dose)</time_frame>
    <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) at Week 4</measure>
    <time_frame>Week 4 (24 h post dose)</time_frame>
    <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) at Week 4</measure>
    <time_frame>Week 4 (24 h post dose)</time_frame>
    <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. CL/F was calculated as dose divided by AUC(0-tau).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) at Week 4</measure>
    <time_frame>Week 4 (24 h post dose)</time_frame>
    <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. Vz/F was calculated as dose divided by (AUC[0-tau] lambda z) where lambda z is the terminal phase rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT Week 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils platelet count and white blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hemoglobin at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of hemoglobin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Hematocrit at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of hematocrit at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of mean corpuscle volume at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Albumin at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of albumin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ALP, ALT, AST, CK and GGT at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Total Bilirubin and Creatinine at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of total bilirubin and creatinine at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment afterl Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in SBP and DBP at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Heart Rate at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from Baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in ECG Heart Rate Values at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>The ECG data was only collected &quot;Perform as needed&quot;, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QTcB, QTcF Values at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>The ECG data was only collected &quot;Perform as needed&quot;, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/BUN at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/bun at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Bun values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points After Week 12</measure>
    <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
    <description>Blood samples were collected for the measurement of estimated creatinine clearance by Cockcroft-Gault formula at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the estimated creatinine clearance values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus eRVR Status</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (eRVR and no eRVE) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected pharmacokinetic parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus eRVR Status</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus eRVR status (eRVR and no eRVR) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus RVR Status</measure>
    <time_frame>Week 4</time_frame>
    <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (RVR and no eVE) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus RVR Status</measure>
    <time_frame>Week 4</time_frame>
    <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus RVR status (RVR and no RVR) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Individual GSK2336805 Dose With Pre-dose Plasma Concentration at Week 4 and Week 12 Versus eRVR Status</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Correlation of individual GSK2336805 dose with pre-dose plasma concentration at Week 4 and Week 12 versus eRVR status was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. The PK/Pharmacodynamic (PD) analysis population comprised of all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable GSK2336805 plasma concentration data considered suitable for investigation of relationship with the PD measures. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation GSK2336805 Pre-dose Plasma Concentration on Day 2 Versus Reduction in HCV RNA on Day 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Correlation GSK2336805 pre-dose plasma concentration (ng/mL) on Day 2 versus reduction in HCV RNA (log IU/mL) on Day 2 was performed. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">286</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>T40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus (HCV) genotype 1 GSK2336805 40 mg, pegylated interferon alpha-2a, and ribavirin arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T60</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus (HCV) genotype 1 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hepatitis C virus (HCV) genotype 1 Telaprevir, pegylated interferon alpha-2a, and ribavirin arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatitis C virus (HCV) genotype 4 GSK2336805 60 mg, pegylated interferon alpha-2a, and ribavirin arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2336805 40 mg</intervention_name>
    <description>20 mg tablet, round, 10-mm diameter, white to off-white, no markings</description>
    <arm_group_label>T40</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2336805 60 mg</intervention_name>
    <description>30 mg tablet, round, 10-mm diameter, white to off-white, no markings</description>
    <arm_group_label>T60</arm_group_label>
    <arm_group_label>G4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alpha-2a</intervention_name>
    <description>180 microgram per 0.5 mL prefilled syringe for single use</description>
    <arm_group_label>PRT</arm_group_label>
    <arm_group_label>T60</arm_group_label>
    <arm_group_label>T40</arm_group_label>
    <arm_group_label>G4</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with &quot;200&quot; on 1 side and the logo &quot;3RP&quot; on the other side</description>
    <arm_group_label>PRT</arm_group_label>
    <arm_group_label>T60</arm_group_label>
    <arm_group_label>T40</arm_group_label>
    <arm_group_label>G4</arm_group_label>
    <other_name>Ribasphere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaprevir</intervention_name>
    <description>375 mg film-coated tablet</description>
    <arm_group_label>PRT</arm_group_label>
    <other_name>Incivek (United States)</other_name>
    <other_name>Incivo (European Union)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Capable of giving written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Male or female aged 18 to 70 years of age, inclusive, at Screening.

          -  Genotype 1 or genotype 4 hepatitis C virus (HCV) infection as assessed by Versant HCV
             Genotype assay 2.0 (LiPA).

          -  Chronic HCV infection documented by at least 1 measurement of serum HCV RNA greater
             than or equal to 100,000 IU/mL measured during Screening by the COBAS High Pure/COBAS
             TaqMan HCV Test v2.0 and at least one of the following:

          -  A positive anti-HCV antibody, HCV RNA, or HCV genotype test at least 6 months prior to
             Baseline (Day 1) together with positive HCV RNA and anti-HCV antibody tests at the
             time of Screening; or

          -  A positive HCV RNA test and anti-HCV antibody test at the time of Screening together
             with either a liver biopsy consistent with chronic HCV infection (or a liver biopsy
             performed before enrollment with evidence of chronic hepatitis C disease, such as the
             presence of fibrosis).

          -  Naïve to all HCV antiviral treatment(s), including, but not limited to,
             immunomodulatory and nucleoside/nucleotide treatments for chronic HCV infection.

          -  Agree to interleukin 28B (IL28B) genotyping.

          -  A subject, who, in the opinion of the investigator, is an appropriate candidate for
             pegylated interferon alpha-2a (PEG)/ribavirin (RIBA)/protease inhibitor combination
             therapy for genotype 1 subjects and PEG/RIBA combination therapy for genotype 4
             subjects.

          -  Body mass index &gt;18 kg/m2 but not exceeding 36 kg/m2.

          -  A liver biopsy obtained within 3 years (36 calendar months) prior to the Day 1 visit,
             with a fibrosis classification of noncirrhotic as judged by a local pathologist
             (defined as Knodell less than or equal to 3, Metavir less than or equal to 2, Ishak
             less than or equal to 4, or Batts and Ludwig less than or equal to 2). Both incomplete
             and transition to cirrhosis (e.g., Metavir score 3) are considered as cirrhosis. If no
             recent (&lt;36 months) liver biopsy is available, a study-qualifying biopsy must be
             performed prior to Baseline (Day 1).

          -  All fertile males and females must use 2 forms of effective contraception between them
             during treatment and during the 24 weeks after treatment ends.

          -  Females, is eligible to enter and participate in the study if of non-childbearing
             potential (i.e., physiologically incapable of becoming pregnant) and includes any
             female who has had a hysterectomy or has had a bilateral oophorectomy (ovariectomy) or
             has had a bilateral tubal ligation or is postmenopausal (demonstrate total cessation
             of menses for greater than 1 year).

          -  Females, is eligible to enter and participate in the study if of childbearing
             potential and has a negative urine or serum pregnancy test at Screening and within the
             24-hour period prior to the first dose of study medication and completely abstains
             from intercourse for 2 weeks before exposure to the study medication, throughout the
             clinical study, and for 24 weeks after completion or premature discontinuation from
             this study or uses 2 of the following acceptable methods of contraception throughout
             the clinical study and for 24 weeks after completion or premature discontinuation from
             this study:

          -  Any intrauterine device with a documented failure rate of &lt;1% per year

          -  Double-barrier contraception (condom, diaphragm, or cervical cap used with spermicidal
             jelly)

          -  Male partner who is sterile prior to the female subject's study entry and is the sole
             sexual partner for that female

          -  Any other contraceptive method with a documented failure rate of &lt;1% per year

          -  Otherwise healthy as determined by the medical history, physical examination, ECG
             findings, and clinical laboratory measurements performed at Screening.

        Exclusion Criteria:

          -  Positive test at Screening visit for hepatitis B surface antigen (HBsAg) or antihuman
             immunodeficiency virus antibody

          -  History of any other clinically significant chronic liver disease (e.g.,
             hemochromatosis, autoimmune hepatitis, Wilson's disease, 1-antitrypsin deficiency,
             alcoholic liver disease, &gt;Grade 1 nonalcoholic steatohepatitis, and toxin exposures).
             Subjects with Gilbert's syndrome who otherwise meet all inclusion/exclusion criteria
             are eligible.

          -  History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions
             consistent with decompensated liver disease

          -  Positive results on urine screen for drugs of abuse test at Screening (unless used as
             medical treatment, e.g., with a prescription)

          -  History of alcohol/drug abuse or dependence within 6 months of the study start (unless
             participating in a controlled rehabilitation program)

          -  Screening visit electrocardiogram corrected QT (QTc) interval value &gt;450 ms and/or
             clinically significant electrocardiogram findings

          -  Personal or family history of Torsade de Pointes findings

          -  Pregnant or nursing

          -  Male with a female partner who is pregnant

          -  Abnormal hematological and biochemical parameters, including:

          -  Neutrophil count &lt;1500 cells/mm3 (or &lt;1250 cells/mm3 for African American/Black
             subjects)

          -  Hemoglobin &lt;11 g/dL in females or &lt;12 g/dL in males

          -  Creatinine greater than or equal to 1.5 × the upper limit of normal (ULN)

          -  Estimated creatinine clearance less than or equal to 50 mL/min (as calculated using
             the Cockcroft-Gault formula)

          -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline
             phosphatase greater than or equal to 5 × ULN

          -  Total bilirubin greater than or equal to 2.0 × ULN (except subjects with Gilbert's
             syndrome)

          -  Albumin less than or equal to 3.0 g/dL

          -  Platelet count less than or equal to 90,000/mm3

          -  History of major organ transplantation with an existing functional graft

          -  Thyroid dysfunction not adequately controlled

          -  History of suicide attempt or hospitalization for depression in the past 5 years

          -  History of any current (within 6 months) severe or poorly controlled psychiatric
             disorder

          -  Subjects who have had a severe or poorly controlled psychiatric disorder more than 6
             months ago but less than 5 years ago are eligible for study participation but must be
             assessed and followed (if recommended) by a mental health professional.

          -  History or current evidence of immunologic disorder; cardiac or pulmonary disease;
             seizure disorder; or cancer or history of malignancy that in the opinion of the
             investigator makes the subject unsuitable for the study.

          -  Treated with herbal or natural remedies with antiviral activity within 30 days of the
             baseline visit or has a history of having received any systemic antineoplastic or
             immunomodulatory treatment (including mycophenolate mofetil, thymosin alpha,
             supraphysiologic doses of steroids &gt;10 mg/day and radiation) within 6 months of the
             baseline visit or expects that such treatment will be needed at any time during the
             study.

          -  Participated in a clinical study with an investigational drug, biologic, or device
             within 3 months prior to the first dose administration.

          -  History of a known allergy to antiviral medications, including telaprevir, pegylated
             interferon alpha-2a (PEG), ribavirin (RIBA), or any excipient in the investigational
             product or history of drug or other allergy that, in the opinion of the investigator,
             contradicts participation.

          -  Requires prohibited medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon Cedex 04</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ponce</city>
        <zip>00716</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Poland</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Protocol contains no citations</citation>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2012</study_first_posted>
  <results_first_submitted>April 25, 2017</results_first_submitted>
  <results_first_submitted_qc>April 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2017</results_first_posted>
  <disposition_first_submitted>February 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 5, 2015</disposition_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genotype 4</keyword>
  <keyword>GSK2336805</keyword>
  <keyword>pegylated interferon</keyword>
  <keyword>telaprevir</keyword>
  <keyword>Genotype 1</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>ribavirin</keyword>
  <keyword>NS5A inhibitor</keyword>
  <keyword>hepatitis C virus (HCV) infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115879</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted across 29 centers in 6 countries (United States, Puerto Rico, Germany, Belgium, France, and Bulgaria) from 15 August 2012 to 16 July 2014.</recruitment_details>
      <pre_assignment_details>Participants with treatment-naïve(TN) chronic genotype1(G1) hepatitis C virus (HCV) infection were randomly allocated on 2:2:1 basis to 2 dose levels of GSK2336805 or telaprevir. In a nonrandomized single-arm cohort, participants with TN genotype4(G4) chronic HCV infection were enrolled in parallel at dose level of 60 milligrams (mg) of GSK2336805.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GSK2336805 40 mg, G1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (Pegylated Interferon Alfa-2a [PEG] + Ribavirin [RIBA]) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the extended rapid virologic response (eRVR) achievement. PEG dose was 180 micrograms (µg) once weekly subcutaneous (SC) injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kilogram [kg]) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
        </group>
        <group group_id="P2">
          <title>GSK2336805 60 mg, G1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="P3">
          <title>Telaprevir, G1 HCV</title>
          <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="P4">
          <title>GSK2336805 60 mg, G4 HCV</title>
          <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GSK2336805 40 mg, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
        </group>
        <group group_id="B2">
          <title>GSK2336805 60 mg, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="B3">
          <title>Telaprevir, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="B4">
          <title>GSK2336805 60 mg, Genotype 4 HCV</title>
          <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" spread="13.23"/>
                    <measurement group_id="B2" value="40.8" spread="9.87"/>
                    <measurement group_id="B3" value="39.4" spread="12.02"/>
                    <measurement group_id="B4" value="45.3" spread="11.46"/>
                    <measurement group_id="B5" value="42.2" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving eRVR</title>
        <description>eRVR is defined as plasma HCV ribonucleic acid (RNA) &lt;lower limit of quantification (LLOQ) and target not detected at Weeks 4 and 12. Participants who discontinued prior to Week 12 assessments or had missing HCV RNA values at Weeks 4 and 12 were treated as non-responders.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>Intent-To-Treat (ITT) Population: comprised of all participants who met the study criteria and were randomly assigned to treatment in the study with documented evidence of having received at least 1 dose of randomized treatment and at least 1 post Baseline HCV RNA measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving eRVR</title>
          <description>eRVR is defined as plasma HCV ribonucleic acid (RNA) &lt;lower limit of quantification (LLOQ) and target not detected at Weeks 4 and 12. Participants who discontinued prior to Week 12 assessments or had missing HCV RNA values at Weeks 4 and 12 were treated as non-responders.</description>
          <population>Intent-To-Treat (ITT) Population: comprised of all participants who met the study criteria and were randomly assigned to treatment in the study with documented evidence of having received at least 1 dose of randomized treatment and at least 1 post Baseline HCV RNA measurement.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12</title>
        <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
        <time_frame>From the start of study treatment up to Week 12</time_frame>
        <population>Safety Population: comprised of all participants who received at least 1 dose of study medication (GSK2336805 or telaprevir).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12</title>
          <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
          <population>Safety Population: comprised of all participants who received at least 1 dose of study medication (GSK2336805 or telaprevir).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12</title>
        <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24. Change from Baseline in SBP and DBP is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) up to 12-week treatment period</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12</title>
          <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and Post-treatment (PT) Follow Up (FU) Weeks 4, 12 and 24. Change from Baseline in SBP and DBP is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP; Day2; n=41, 40, 17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="6.63"/>
                    <measurement group_id="O2" value="-1" spread="7.03"/>
                    <measurement group_id="O3" value="-3" spread="9.03"/>
                    <measurement group_id="O4" value="-1.5" spread="10.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week1; n=41, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="7.98"/>
                    <measurement group_id="O2" value="-2.2" spread="9.13"/>
                    <measurement group_id="O3" value="1" spread="10.54"/>
                    <measurement group_id="O4" value="-1" spread="7.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week2; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="10.41"/>
                    <measurement group_id="O2" value="-1.7" spread="9.52"/>
                    <measurement group_id="O3" value="-0.3" spread="8.8"/>
                    <measurement group_id="O4" value="-2.8" spread="11.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="7.73"/>
                    <measurement group_id="O2" value="-4.4" spread="9.78"/>
                    <measurement group_id="O3" value="-3.9" spread="9.74"/>
                    <measurement group_id="O4" value="0.8" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week6; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="7.65"/>
                    <measurement group_id="O2" value="-4.8" spread="9.86"/>
                    <measurement group_id="O3" value="-5.9" spread="7.82"/>
                    <measurement group_id="O4" value="-1.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week8; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="10"/>
                    <measurement group_id="O2" value="-2.9" spread="9.11"/>
                    <measurement group_id="O3" value="-4.4" spread="7.63"/>
                    <measurement group_id="O4" value="-2.4" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP; Week12; n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="8.48"/>
                    <measurement group_id="O2" value="-4.4" spread="10.24"/>
                    <measurement group_id="O3" value="-3.5" spread="9.2"/>
                    <measurement group_id="O4" value="-1" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Day2; n=41, 40, 17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="10.1"/>
                    <measurement group_id="O2" value="-0.8" spread="12.85"/>
                    <measurement group_id="O3" value="-3.3" spread="10.46"/>
                    <measurement group_id="O4" value="-1.3" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week1; n=41, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="12.99"/>
                    <measurement group_id="O2" value="-3" spread="11.24"/>
                    <measurement group_id="O3" value="-4.5" spread="12.67"/>
                    <measurement group_id="O4" value="-2.6" spread="11.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week2; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="10.57"/>
                    <measurement group_id="O2" value="-0.7" spread="11.67"/>
                    <measurement group_id="O3" value="-4.1" spread="12.67"/>
                    <measurement group_id="O4" value="-4.2" spread="17.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="11.56"/>
                    <measurement group_id="O2" value="-4.2" spread="16.2"/>
                    <measurement group_id="O3" value="-3.8" spread="9.73"/>
                    <measurement group_id="O4" value="-5.2" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week6; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="14.47"/>
                    <measurement group_id="O2" value="-3.8" spread="13.28"/>
                    <measurement group_id="O3" value="-5.9" spread="11.39"/>
                    <measurement group_id="O4" value="0.2" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week8; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="12.15"/>
                    <measurement group_id="O2" value="-1.5" spread="12.64"/>
                    <measurement group_id="O3" value="-2.9" spread="10.36"/>
                    <measurement group_id="O4" value="-4.2" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP; Week12; n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="13.65"/>
                    <measurement group_id="O2" value="-1.4" spread="11.72"/>
                    <measurement group_id="O3" value="-5.2" spread="5.81"/>
                    <measurement group_id="O4" value="-2.6" spread="19.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12</title>
        <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4, 12 and 24. Change from Baseline in heart rate is summarized for each post-Baseline assessment upto Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Day 2, Weeks 1, 2, 4, 6, 8, and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12</title>
          <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4, 12 and 24. Change from Baseline in heart rate is summarized for each post-Baseline assessment upto Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate; Day2; n=41, 40, 17, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="8.65"/>
                    <measurement group_id="O2" value="5.4" spread="9.96"/>
                    <measurement group_id="O3" value="9.3" spread="11.74"/>
                    <measurement group_id="O4" value="3.8" spread="5.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week1; n=41, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="8.33"/>
                    <measurement group_id="O2" value="3.1" spread="8.75"/>
                    <measurement group_id="O3" value="8.1" spread="6.32"/>
                    <measurement group_id="O4" value="7.7" spread="10.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week2; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="9.02"/>
                    <measurement group_id="O2" value="4.2" spread="12.14"/>
                    <measurement group_id="O3" value="8.7" spread="8.17"/>
                    <measurement group_id="O4" value="7.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="9.42"/>
                    <measurement group_id="O2" value="4.2" spread="11.78"/>
                    <measurement group_id="O3" value="10.7" spread="11.39"/>
                    <measurement group_id="O4" value="5.5" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week6; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8" spread="10.15"/>
                    <measurement group_id="O2" value="5" spread="10.98"/>
                    <measurement group_id="O3" value="13.8" spread="9.75"/>
                    <measurement group_id="O4" value="10.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week8; n=41, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="9.91"/>
                    <measurement group_id="O2" value="6.8" spread="12.42"/>
                    <measurement group_id="O3" value="14.2" spread="10.36"/>
                    <measurement group_id="O4" value="12.8" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate; Week12; n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="9.2"/>
                    <measurement group_id="O2" value="5.3" spread="12.1"/>
                    <measurement group_id="O3" value="11" spread="8.02"/>
                    <measurement group_id="O4" value="8.4" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils, platelet count and white blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils, platelet count and white blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Giga cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.011" spread="0.0191"/>
                    <measurement group_id="O2" value="-0.011" spread="0.0193"/>
                    <measurement group_id="O3" value="-0.012" spread="0.0105"/>
                    <measurement group_id="O4" value="-0.013" spread="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.0175"/>
                    <measurement group_id="O2" value="-0.01" spread="0.0192"/>
                    <measurement group_id="O3" value="-0.009" spread="0.0107"/>
                    <measurement group_id="O4" value="-0.009" spread="0.0179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.017" spread="0.0184"/>
                    <measurement group_id="O2" value="-0.012" spread="0.0187"/>
                    <measurement group_id="O3" value="-0.01" spread="0.0118"/>
                    <measurement group_id="O4" value="-0.015" spread="0.0113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.021"/>
                    <measurement group_id="O2" value="-0.013" spread="0.0205"/>
                    <measurement group_id="O3" value="-0.013" spread="0.0114"/>
                    <measurement group_id="O4" value="-0.013" spread="0.0106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.0155"/>
                    <measurement group_id="O2" value="-0.016" spread="0.018"/>
                    <measurement group_id="O3" value="-0.009" spread="0.0132"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.0184"/>
                    <measurement group_id="O2" value="-0.013" spread="0.0187"/>
                    <measurement group_id="O3" value="-0.011" spread="0.0124"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.051" spread="0.0874"/>
                    <measurement group_id="O2" value="-0.075" spread="0.106"/>
                    <measurement group_id="O3" value="-0.059" spread="0.0578"/>
                    <measurement group_id="O4" value="-0.085" spread="0.1052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.1004"/>
                    <measurement group_id="O2" value="-0.111" spread="0.0912"/>
                    <measurement group_id="O3" value="-0.059" spread="0.104"/>
                    <measurement group_id="O4" value="-0.114" spread="0.1247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.105" spread="0.0872"/>
                    <measurement group_id="O2" value="-0.132" spread="0.1057"/>
                    <measurement group_id="O3" value="-0.079" spread="0.1089"/>
                    <measurement group_id="O4" value="-0.108" spread="0.0923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.117" spread="0.0929"/>
                    <measurement group_id="O2" value="-0.134" spread="0.1182"/>
                    <measurement group_id="O3" value="-0.113" spread="0.0607"/>
                    <measurement group_id="O4" value="-0.109" spread="0.1208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.121" spread="0.0897"/>
                    <measurement group_id="O2" value="-0.134" spread="0.1061"/>
                    <measurement group_id="O3" value="-0.13" spread="0.0965"/>
                    <measurement group_id="O4" value="-0.104" spread="0.0916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.118" spread="0.0916"/>
                    <measurement group_id="O2" value="-0.112" spread="0.1594"/>
                    <measurement group_id="O3" value="-0.106" spread="0.1152"/>
                    <measurement group_id="O4" value="-0.102" spread="0.1428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.319" spread="0.5006"/>
                    <measurement group_id="O2" value="-0.282" spread="0.5698"/>
                    <measurement group_id="O3" value="-0.608" spread="0.5466"/>
                    <measurement group_id="O4" value="-0.371" spread="0.4332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.448" spread="0.5385"/>
                    <measurement group_id="O2" value="-0.603" spread="0.5921"/>
                    <measurement group_id="O3" value="-0.675" spread="0.5639"/>
                    <measurement group_id="O4" value="-0.553" spread="0.4346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.787" spread="0.5055"/>
                    <measurement group_id="O2" value="-0.854" spread="0.5114"/>
                    <measurement group_id="O3" value="-0.989" spread="0.5293"/>
                    <measurement group_id="O4" value="-0.773" spread="0.4104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.963" spread="0.5313"/>
                    <measurement group_id="O2" value="-1.043" spread="0.5928"/>
                    <measurement group_id="O3" value="-1.334" spread="0.4906"/>
                    <measurement group_id="O4" value="-0.93" spread="0.4955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.953" spread="0.4624"/>
                    <measurement group_id="O2" value="-1.061" spread="0.6021"/>
                    <measurement group_id="O3" value="-1.256" spread="0.3509"/>
                    <measurement group_id="O4" value="-0.964" spread="0.5098"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.118" spread="0.5139"/>
                    <measurement group_id="O2" value="-1.074" spread="0.5883"/>
                    <measurement group_id="O3" value="-1.438" spread="0.4773"/>
                    <measurement group_id="O4" value="-1.048" spread="0.6612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.103" spread="0.1418"/>
                    <measurement group_id="O2" value="-0.056" spread="0.145"/>
                    <measurement group_id="O3" value="0.034" spread="0.1502"/>
                    <measurement group_id="O4" value="-0.025" spread="0.0808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.122" spread="0.227"/>
                    <measurement group_id="O2" value="-0.061" spread="0.1785"/>
                    <measurement group_id="O3" value="-0.091" spread="0.1562"/>
                    <measurement group_id="O4" value="-0.034" spread="0.1687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.151" spread="0.1771"/>
                    <measurement group_id="O2" value="-0.129" spread="0.158"/>
                    <measurement group_id="O3" value="-0.126" spread="0.1471"/>
                    <measurement group_id="O4" value="-0.055" spread="0.2103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.182" spread="0.1664"/>
                    <measurement group_id="O2" value="-0.171" spread="0.1326"/>
                    <measurement group_id="O3" value="-0.245" spread="0.1786"/>
                    <measurement group_id="O4" value="-0.135" spread="0.1088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.229" spread="0.167"/>
                    <measurement group_id="O2" value="-0.165" spread="0.1779"/>
                    <measurement group_id="O3" value="-0.185" spread="0.1344"/>
                    <measurement group_id="O4" value="-0.124" spread="0.2164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.185" spread="0.1715"/>
                    <measurement group_id="O2" value="-0.183" spread="0.1438"/>
                    <measurement group_id="O3" value="-0.219" spread="0.1493"/>
                    <measurement group_id="O4" value="-0.133" spread="0.2048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.338" spread="1.4959"/>
                    <measurement group_id="O2" value="-1.871" spread="1.5089"/>
                    <measurement group_id="O3" value="-1.158" spread="1.2688"/>
                    <measurement group_id="O4" value="-1.378" spread="0.598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week 2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.114" spread="1.9189"/>
                    <measurement group_id="O2" value="-2.121" spread="1.6445"/>
                    <measurement group_id="O3" value="-1.186" spread="1.3343"/>
                    <measurement group_id="O4" value="-1.468" spread="0.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.487" spread="1.9145"/>
                    <measurement group_id="O2" value="-2.333" spread="1.5497"/>
                    <measurement group_id="O3" value="-1.412" spread="1.5704"/>
                    <measurement group_id="O4" value="-1.603" spread="0.5953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="1.8144"/>
                    <measurement group_id="O2" value="-2.247" spread="1.5132"/>
                    <measurement group_id="O3" value="-1.413" spread="1.4303"/>
                    <measurement group_id="O4" value="-1.683" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.706" spread="1.7553"/>
                    <measurement group_id="O2" value="-2.168" spread="1.6902"/>
                    <measurement group_id="O3" value="-1.222" spread="1.3481"/>
                    <measurement group_id="O4" value="-1.613" spread="0.6882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.894" spread="1.8124"/>
                    <measurement group_id="O2" value="-2.188" spread="1.7297"/>
                    <measurement group_id="O3" value="-1.649" spread="0.8749"/>
                    <measurement group_id="O4" value="-1.483" spread="0.5873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week1; n=38, 39, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.5" spread="36.23"/>
                    <measurement group_id="O2" value="-51.4" spread="36.42"/>
                    <measurement group_id="O3" value="-59.5" spread="36.29"/>
                    <measurement group_id="O4" value="-33.1" spread="33.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week2; n=41, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58" spread="43.92"/>
                    <measurement group_id="O2" value="-57.8" spread="44.02"/>
                    <measurement group_id="O3" value="-41.4" spread="37.44"/>
                    <measurement group_id="O4" value="-34.4" spread="41.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.4" spread="49.18"/>
                    <measurement group_id="O2" value="-55.9" spread="47.19"/>
                    <measurement group_id="O3" value="-56.2" spread="50.99"/>
                    <measurement group_id="O4" value="-33.8" spread="61.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week6; n=41, 38, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.8" spread="50.43"/>
                    <measurement group_id="O2" value="-71.9" spread="38.6"/>
                    <measurement group_id="O3" value="-71.3" spread="47.07"/>
                    <measurement group_id="O4" value="-46" spread="46.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week8; n=39, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74.9" spread="42.31"/>
                    <measurement group_id="O2" value="-75.7" spread="45.82"/>
                    <measurement group_id="O3" value="-60.1" spread="43.26"/>
                    <measurement group_id="O4" value="-52.6" spread="43.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week12; n=38, 34, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.4" spread="45.3"/>
                    <measurement group_id="O2" value="-85.3" spread="40.42"/>
                    <measurement group_id="O3" value="-58.8" spread="58.77"/>
                    <measurement group_id="O4" value="-53" spread="39.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week1; n=38, 38, 14, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.83" spread="1.705"/>
                    <measurement group_id="O2" value="-2.3" spread="1.872"/>
                    <measurement group_id="O3" value="-1.81" spread="1.516"/>
                    <measurement group_id="O4" value="-1.87" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week2; n=40, 38, 14, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.77" spread="2.178"/>
                    <measurement group_id="O2" value="-2.92" spread="1.81"/>
                    <measurement group_id="O3" value="-2.01" spread="1.869"/>
                    <measurement group_id="O4" value="-2.17" spread="0.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.55" spread="2.183"/>
                    <measurement group_id="O2" value="-3.47" spread="1.712"/>
                    <measurement group_id="O3" value="-2.61" spread="2.055"/>
                    <measurement group_id="O4" value="-2.55" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week6; n=41, 37, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.78" spread="2.051"/>
                    <measurement group_id="O2" value="-3.62" spread="1.682"/>
                    <measurement group_id="O3" value="-3.09" spread="1.69"/>
                    <measurement group_id="O4" value="-2.85" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week8; n=38, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.03" spread="2.028"/>
                    <measurement group_id="O2" value="-3.55" spread="1.896"/>
                    <measurement group_id="O3" value="-2.8" spread="1.477"/>
                    <measurement group_id="O4" value="-2.8" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week12; n=37, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.33" spread="2.149"/>
                    <measurement group_id="O2" value="-3.58" spread="1.934"/>
                    <measurement group_id="O3" value="-3.42" spread="1.104"/>
                    <measurement group_id="O4" value="-2.77" spread="0.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Trillion cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell count; Week1; n=38, 39, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.226"/>
                    <measurement group_id="O2" value="-0.04" spread="0.279"/>
                    <measurement group_id="O3" value="-0.18" spread="0.212"/>
                    <measurement group_id="O4" value="-0.13" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week2; n=41, 38, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.376"/>
                    <measurement group_id="O2" value="-0.44" spread="0.508"/>
                    <measurement group_id="O3" value="-0.57" spread="0.312"/>
                    <measurement group_id="O4" value="-0.28" spread="0.361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.507"/>
                    <measurement group_id="O2" value="-0.64" spread="0.623"/>
                    <measurement group_id="O3" value="-1.03" spread="0.441"/>
                    <measurement group_id="O4" value="-0.72" spread="0.559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week6; n=41, 38, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.97" spread="0.504"/>
                    <measurement group_id="O2" value="-0.78" spread="0.563"/>
                    <measurement group_id="O3" value="-1.28" spread="0.49"/>
                    <measurement group_id="O4" value="-0.86" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week8; n=39, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.01" spread="0.506"/>
                    <measurement group_id="O2" value="-0.82" spread="0.534"/>
                    <measurement group_id="O3" value="-1.45" spread="0.357"/>
                    <measurement group_id="O4" value="-0.85" spread="0.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week12; n=38, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.48"/>
                    <measurement group_id="O2" value="-0.79" spread="0.56"/>
                    <measurement group_id="O3" value="-1.61" spread="0.464"/>
                    <measurement group_id="O4" value="-0.92" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of hemoglobin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of hemoglobin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Week1; n=38, 39, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="6.98"/>
                    <measurement group_id="O2" value="-2.3" spread="9.38"/>
                    <measurement group_id="O3" value="-6.6" spread="5.83"/>
                    <measurement group_id="O4" value="-5.3" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week2; n=41, 38, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="12.54"/>
                    <measurement group_id="O2" value="-14.9" spread="16.21"/>
                    <measurement group_id="O3" value="-20.5" spread="10.66"/>
                    <measurement group_id="O4" value="-9.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="15.38"/>
                    <measurement group_id="O2" value="-22.1" spread="18.98"/>
                    <measurement group_id="O3" value="-34.4" spread="13.55"/>
                    <measurement group_id="O4" value="-22.5" spread="14.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week6; n=41, 38, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.1" spread="14.54"/>
                    <measurement group_id="O2" value="-24.7" spread="16"/>
                    <measurement group_id="O3" value="-40.8" spread="14.11"/>
                    <measurement group_id="O4" value="-25.2" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week8; n=39, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.5" spread="13.29"/>
                    <measurement group_id="O2" value="-25.5" spread="14.22"/>
                    <measurement group_id="O3" value="-44.9" spread="11.73"/>
                    <measurement group_id="O4" value="-25.2" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week12; n=38, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" spread="12.88"/>
                    <measurement group_id="O2" value="-24.1" spread="13.41"/>
                    <measurement group_id="O3" value="-47.4" spread="14.12"/>
                    <measurement group_id="O4" value="-27.6" spread="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of hematocrit at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of hematocrit at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; Week1; n=38, 39, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0196" spread="0.02345"/>
                    <measurement group_id="O2" value="-0.0069" spread="0.02751"/>
                    <measurement group_id="O3" value="-0.0201" spread="0.01921"/>
                    <measurement group_id="O4" value="-0.0166" spread="0.0298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week2; n=41, 38, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0539" spread="0.03653"/>
                    <measurement group_id="O2" value="-0.0465" spread="0.04738"/>
                    <measurement group_id="O3" value="-0.0609" spread="0.03007"/>
                    <measurement group_id="O4" value="-0.0335" spread="0.03625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0848" spread="0.04576"/>
                    <measurement group_id="O2" value="-0.0621" spread="0.05468"/>
                    <measurement group_id="O3" value="-0.0999" spread="0.03967"/>
                    <measurement group_id="O4" value="-0.0668" spread="0.04445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week6; n=41, 38, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0859" spread="0.0411"/>
                    <measurement group_id="O2" value="-0.0685" spread="0.04487"/>
                    <measurement group_id="O3" value="-0.1203" spread="0.04463"/>
                    <measurement group_id="O4" value="-0.074" spread="0.03316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week8; n=39, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0838" spread="0.03955"/>
                    <measurement group_id="O2" value="-0.0663" spread="0.04144"/>
                    <measurement group_id="O3" value="-0.1235" spread="0.03288"/>
                    <measurement group_id="O4" value="-0.07" spread="0.02758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week12; n=38, 36, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0843" spread="0.04038"/>
                    <measurement group_id="O2" value="-0.0589" spread="0.03648"/>
                    <measurement group_id="O3" value="-0.1318" spread="0.03847"/>
                    <measurement group_id="O4" value="-0.0688" spread="0.03298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of mean corpuscle volume at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean corpuscle volume; Week1; n=38, 39, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.21"/>
                    <measurement group_id="O2" value="-0.8" spread="1.37"/>
                    <measurement group_id="O3" value="-0.4" spread="1.15"/>
                    <measurement group_id="O4" value="-0.7" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week2; n=41, 38, 14, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="1.84"/>
                    <measurement group_id="O2" value="-1.4" spread="1.59"/>
                    <measurement group_id="O3" value="-1.4" spread="1.09"/>
                    <measurement group_id="O4" value="-1.5" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week4; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.33"/>
                    <measurement group_id="O2" value="0.2" spread="3.4"/>
                    <measurement group_id="O3" value="-0.8" spread="1.58"/>
                    <measurement group_id="O4" value="-0.2" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week6; n=41, 38, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="4.76"/>
                    <measurement group_id="O2" value="1.8" spread="4.67"/>
                    <measurement group_id="O3" value="-0.2" spread="2.37"/>
                    <measurement group_id="O4" value="1.4" spread="4.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week8; n=39, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="5.39"/>
                    <measurement group_id="O2" value="3" spread="5.2"/>
                    <measurement group_id="O3" value="3.1" spread="2.78"/>
                    <measurement group_id="O4" value="2.2" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean corpuscle volume; Week12; n=38, 34, 12, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="6"/>
                    <measurement group_id="O2" value="4.2" spread="6.3"/>
                    <measurement group_id="O3" value="5.3" spread="4.14"/>
                    <measurement group_id="O4" value="3.8" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of albumin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of albumin at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.67"/>
                    <measurement group_id="O2" value="-0.3" spread="2.46"/>
                    <measurement group_id="O3" value="-1.1" spread="1.6"/>
                    <measurement group_id="O4" value="-1" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.98"/>
                    <measurement group_id="O2" value="-1.5" spread="2.68"/>
                    <measurement group_id="O3" value="-2" spread="2.6"/>
                    <measurement group_id="O4" value="-0.2" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="2.48"/>
                    <measurement group_id="O2" value="-1.5" spread="2.52"/>
                    <measurement group_id="O3" value="-3" spread="3.21"/>
                    <measurement group_id="O4" value="-1.2" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.65"/>
                    <measurement group_id="O2" value="-1.5" spread="2.27"/>
                    <measurement group_id="O3" value="-3.5" spread="3.36"/>
                    <measurement group_id="O4" value="-2.1" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.99"/>
                    <measurement group_id="O2" value="-1.7" spread="2"/>
                    <measurement group_id="O3" value="-3.7" spread="4.71"/>
                    <measurement group_id="O4" value="-1.5" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.03"/>
                    <measurement group_id="O2" value="-1.3" spread="2.84"/>
                    <measurement group_id="O3" value="-3.3" spread="3.02"/>
                    <measurement group_id="O4" value="-1.6" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4 Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4 Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="7.73"/>
                    <measurement group_id="O2" value="1.5" spread="10.21"/>
                    <measurement group_id="O3" value="3.9" spread="19.36"/>
                    <measurement group_id="O4" value="-0.2" spread="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="9.26"/>
                    <measurement group_id="O2" value="3.8" spread="16.22"/>
                    <measurement group_id="O3" value="9.4" spread="21.15"/>
                    <measurement group_id="O4" value="3.8" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="11.12"/>
                    <measurement group_id="O2" value="7.1" spread="13.76"/>
                    <measurement group_id="O3" value="11.7" spread="26.61"/>
                    <measurement group_id="O4" value="7.2" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="13.73"/>
                    <measurement group_id="O2" value="7.2" spread="17.1"/>
                    <measurement group_id="O3" value="16.6" spread="31.03"/>
                    <measurement group_id="O4" value="6.6" spread="16.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="15.59"/>
                    <measurement group_id="O2" value="6.5" spread="15.91"/>
                    <measurement group_id="O3" value="15.5" spread="25.83"/>
                    <measurement group_id="O4" value="5.6" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="15.56"/>
                    <measurement group_id="O2" value="6.4" spread="20.78"/>
                    <measurement group_id="O3" value="11.7" spread="25.09"/>
                    <measurement group_id="O4" value="7.3" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="31.64"/>
                    <measurement group_id="O2" value="-24.4" spread="32.39"/>
                    <measurement group_id="O3" value="-30.7" spread="30.1"/>
                    <measurement group_id="O4" value="-25.6" spread="20.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.2" spread="40.33"/>
                    <measurement group_id="O2" value="-24.9" spread="47.49"/>
                    <measurement group_id="O3" value="-35.4" spread="36.38"/>
                    <measurement group_id="O4" value="-26.8" spread="24.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="44.5"/>
                    <measurement group_id="O2" value="-25.3" spread="50.87"/>
                    <measurement group_id="O3" value="-40.4" spread="38.73"/>
                    <measurement group_id="O4" value="-33" spread="28.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36" spread="49.77"/>
                    <measurement group_id="O2" value="-30.3" spread="50.74"/>
                    <measurement group_id="O3" value="-40.8" spread="41.51"/>
                    <measurement group_id="O4" value="-38.4" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.8" spread="55.75"/>
                    <measurement group_id="O2" value="-25.4" spread="55.92"/>
                    <measurement group_id="O3" value="-39.9" spread="40.27"/>
                    <measurement group_id="O4" value="-39.5" spread="29.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="59.7"/>
                    <measurement group_id="O2" value="-23.5" spread="59.69"/>
                    <measurement group_id="O3" value="-43.7" spread="40.45"/>
                    <measurement group_id="O4" value="-36.8" spread="24.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="16.28"/>
                    <measurement group_id="O2" value="-15.2" spread="21.55"/>
                    <measurement group_id="O3" value="-18.1" spread="21.77"/>
                    <measurement group_id="O4" value="-13.9" spread="10.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="20.84"/>
                    <measurement group_id="O2" value="-11.6" spread="26.3"/>
                    <measurement group_id="O3" value="-18.4" spread="23.52"/>
                    <measurement group_id="O4" value="-10.2" spread="12.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="21.45"/>
                    <measurement group_id="O2" value="-10.6" spread="27.4"/>
                    <measurement group_id="O3" value="-20.9" spread="25.86"/>
                    <measurement group_id="O4" value="-15.8" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="21.56"/>
                    <measurement group_id="O2" value="-13.8" spread="25.01"/>
                    <measurement group_id="O3" value="-21.6" spread="28.43"/>
                    <measurement group_id="O4" value="-19.5" spread="12.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="26.01"/>
                    <measurement group_id="O2" value="-7.6" spread="38.38"/>
                    <measurement group_id="O3" value="-21.8" spread="26.38"/>
                    <measurement group_id="O4" value="-18.6" spread="12.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="25.58"/>
                    <measurement group_id="O2" value="-6.5" spread="36.17"/>
                    <measurement group_id="O3" value="-25.7" spread="27.32"/>
                    <measurement group_id="O4" value="-17.3" spread="12.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="82.13"/>
                    <measurement group_id="O2" value="-10.9" spread="103.31"/>
                    <measurement group_id="O3" value="-3.3" spread="32.1"/>
                    <measurement group_id="O4" value="-43.5" spread="82.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="53.87"/>
                    <measurement group_id="O2" value="-22.6" spread="77.26"/>
                    <measurement group_id="O3" value="-9.6" spread="36.26"/>
                    <measurement group_id="O4" value="-28.5" spread="54.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="141.46"/>
                    <measurement group_id="O2" value="-32.1" spread="59.61"/>
                    <measurement group_id="O3" value="-14.4" spread="22.06"/>
                    <measurement group_id="O4" value="-47.7" spread="59.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26" spread="63.11"/>
                    <measurement group_id="O2" value="56.1" spread="566.79"/>
                    <measurement group_id="O3" value="-21.5" spread="48.49"/>
                    <measurement group_id="O4" value="-64.5" spread="110.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="95.03"/>
                    <measurement group_id="O2" value="-33.2" spread="65.96"/>
                    <measurement group_id="O3" value="-30.3" spread="51.17"/>
                    <measurement group_id="O4" value="-66.8" spread="107.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36.3" spread="75.56"/>
                    <measurement group_id="O2" value="-33.9" spread="47.72"/>
                    <measurement group_id="O3" value="-20.9" spread="59.82"/>
                    <measurement group_id="O4" value="-48.5" spread="61.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.7" spread="20.79"/>
                    <measurement group_id="O2" value="-2" spread="16.83"/>
                    <measurement group_id="O3" value="-10.3" spread="19.38"/>
                    <measurement group_id="O4" value="-6.4" spread="23.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.7" spread="33.78"/>
                    <measurement group_id="O2" value="-17.1" spread="45.23"/>
                    <measurement group_id="O3" value="-19.9" spread="29.59"/>
                    <measurement group_id="O4" value="-7.2" spread="29.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="52.93"/>
                    <measurement group_id="O2" value="-25.5" spread="59.64"/>
                    <measurement group_id="O3" value="-27.7" spread="36.64"/>
                    <measurement group_id="O4" value="-16.2" spread="36.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.1" spread="67.33"/>
                    <measurement group_id="O2" value="-30.5" spread="72.27"/>
                    <measurement group_id="O3" value="-30.5" spread="44.3"/>
                    <measurement group_id="O4" value="-23.8" spread="39.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.1" spread="70.41"/>
                    <measurement group_id="O2" value="-27.2" spread="80.33"/>
                    <measurement group_id="O3" value="-30.5" spread="45.05"/>
                    <measurement group_id="O4" value="-28.5" spread="45.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.7" spread="80.2"/>
                    <measurement group_id="O2" value="-20.7" spread="73.43"/>
                    <measurement group_id="O3" value="-33.6" spread="49.61"/>
                    <measurement group_id="O4" value="-30" spread="53.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin and creatinine at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of direct bilirubin, total bilirubin and creatinine at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Bilirubin; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="8.74"/>
                    <measurement group_id="O2" value="6.7" spread="8.93"/>
                    <measurement group_id="O3" value="8.1" spread="11.81"/>
                    <measurement group_id="O4" value="4.2" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="6.62"/>
                    <measurement group_id="O2" value="5.5" spread="6.84"/>
                    <measurement group_id="O3" value="5.6" spread="9.8"/>
                    <measurement group_id="O4" value="6.5" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.03"/>
                    <measurement group_id="O2" value="2.9" spread="3.52"/>
                    <measurement group_id="O3" value="0.7" spread="8.94"/>
                    <measurement group_id="O4" value="2.5" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="4.14"/>
                    <measurement group_id="O2" value="2.7" spread="3.97"/>
                    <measurement group_id="O3" value="-0.5" spread="9.09"/>
                    <measurement group_id="O4" value="2.1" spread="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="4.63"/>
                    <measurement group_id="O2" value="2.3" spread="4.93"/>
                    <measurement group_id="O3" value="-0.3" spread="9.83"/>
                    <measurement group_id="O4" value="1.8" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="4.46"/>
                    <measurement group_id="O2" value="1.4" spread="5.61"/>
                    <measurement group_id="O3" value="-2.8" spread="10.04"/>
                    <measurement group_id="O4" value="1.2" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week1; n=1, 1, 1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">A value of NA indicates not applicable</measurement>
                    <measurement group_id="O2" value="2">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O3" value="-8">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O4" value="-1">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week2; n=1, 1, 1, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O2" value="0">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O3" value="-14">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O4" value="1">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week4; n=1, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O2" value="2">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O3" value="NA">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O4" value="NA">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Direct Bilirubin; Week6; n=1, 1, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O2" value="0">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O3" value="NA">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                    <measurement group_id="O4" value="NA">too few participants or number of participants were analyzed at the indicated test/time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="5.983"/>
                    <measurement group_id="O2" value="0.23" spread="5.446"/>
                    <measurement group_id="O3" value="5.12" spread="7.883"/>
                    <measurement group_id="O4" value="-3.85" spread="5.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.47" spread="7.966"/>
                    <measurement group_id="O2" value="-2.78" spread="5.725"/>
                    <measurement group_id="O3" value="4.13" spread="6.518"/>
                    <measurement group_id="O4" value="-1.17" spread="7.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="5.894"/>
                    <measurement group_id="O2" value="-1.33" spread="6.403"/>
                    <measurement group_id="O3" value="5.35" spread="10.16"/>
                    <measurement group_id="O4" value="-3.57" spread="9.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="6.18"/>
                    <measurement group_id="O2" value="-0.34" spread="7.667"/>
                    <measurement group_id="O3" value="7.1" spread="7.905"/>
                    <measurement group_id="O4" value="-2.05" spread="9.365"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="5.724"/>
                    <measurement group_id="O2" value="-0.51" spread="5.425"/>
                    <measurement group_id="O3" value="9.43" spread="10.839"/>
                    <measurement group_id="O4" value="-0.08" spread="10.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week12; n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="8.411"/>
                    <measurement group_id="O2" value="-1.99" spread="8.704"/>
                    <measurement group_id="O3" value="6.85" spread="10.363"/>
                    <measurement group_id="O4" value="-2.41" spread="12.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/BUN values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chloride; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.1"/>
                    <measurement group_id="O2" value="-0.4" spread="2.03"/>
                    <measurement group_id="O3" value="0.6" spread="2.61"/>
                    <measurement group_id="O4" value="-0.2" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.37"/>
                    <measurement group_id="O2" value="0.1" spread="1.9"/>
                    <measurement group_id="O3" value="0.5" spread="1.61"/>
                    <measurement group_id="O4" value="-0.7" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.31"/>
                    <measurement group_id="O2" value="1" spread="2.46"/>
                    <measurement group_id="O3" value="1.6" spread="2.21"/>
                    <measurement group_id="O4" value="0.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.62"/>
                    <measurement group_id="O2" value="0.8" spread="2.57"/>
                    <measurement group_id="O3" value="0.8" spread="2.73"/>
                    <measurement group_id="O4" value="-0.1" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="3.49"/>
                    <measurement group_id="O2" value="0.7" spread="2.36"/>
                    <measurement group_id="O3" value="2.2" spread="3"/>
                    <measurement group_id="O4" value="-0.8" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.36"/>
                    <measurement group_id="O2" value="0.1" spread="3.35"/>
                    <measurement group_id="O3" value="1.9" spread="2.61"/>
                    <measurement group_id="O4" value="1.2" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="3.05"/>
                    <measurement group_id="O2" value="-0.9" spread="2.57"/>
                    <measurement group_id="O3" value="-1.2" spread="2.54"/>
                    <measurement group_id="O4" value="-0.7" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.2"/>
                    <measurement group_id="O2" value="-0.8" spread="3.1"/>
                    <measurement group_id="O3" value="-1.5" spread="2.98"/>
                    <measurement group_id="O4" value="-0.2" spread="3.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.91"/>
                    <measurement group_id="O2" value="-0.8" spread="2.55"/>
                    <measurement group_id="O3" value="-1.4" spread="1.86"/>
                    <measurement group_id="O4" value="-0.5" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2"/>
                    <measurement group_id="O2" value="-0.7" spread="2.23"/>
                    <measurement group_id="O3" value="-1.5" spread="2.18"/>
                    <measurement group_id="O4" value="0.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.41"/>
                    <measurement group_id="O2" value="-0.8" spread="2.35"/>
                    <measurement group_id="O3" value="-1.2" spread="2.19"/>
                    <measurement group_id="O4" value="0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.42"/>
                    <measurement group_id="O2" value="-0.9" spread="2.37"/>
                    <measurement group_id="O3" value="-1.1" spread="2.23"/>
                    <measurement group_id="O4" value="-0.5" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="1.485"/>
                    <measurement group_id="O2" value="-0.34" spread="0.761"/>
                    <measurement group_id="O3" value="-0.03" spread="0.616"/>
                    <measurement group_id="O4" value="0.36" spread="1.619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.467"/>
                    <measurement group_id="O2" value="-0.17" spread="0.791"/>
                    <measurement group_id="O3" value="0.11" spread="0.52"/>
                    <measurement group_id="O4" value="0.13" spread="1.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.162"/>
                    <measurement group_id="O2" value="0.02" spread="1.054"/>
                    <measurement group_id="O3" value="-0.11" spread="0.601"/>
                    <measurement group_id="O4" value="-0.48" spread="0.832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="1.315"/>
                    <measurement group_id="O2" value="-0.18" spread="1.154"/>
                    <measurement group_id="O3" value="0.18" spread="0.772"/>
                    <measurement group_id="O4" value="-0.55" spread="0.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="1.165"/>
                    <measurement group_id="O2" value="-0.06" spread="0.835"/>
                    <measurement group_id="O3" value="0.04" spread="0.675"/>
                    <measurement group_id="O4" value="-0.36" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week12; n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.877"/>
                    <measurement group_id="O2" value="-0.39" spread="1.047"/>
                    <measurement group_id="O3" value="-0.23" spread="0.757"/>
                    <measurement group_id="O4" value="-0.45" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.392"/>
                    <measurement group_id="O2" value="-0.06" spread="0.339"/>
                    <measurement group_id="O3" value="-0.11" spread="0.376"/>
                    <measurement group_id="O4" value="-0.02" spread="0.313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.428"/>
                    <measurement group_id="O2" value="-0.12" spread="0.453"/>
                    <measurement group_id="O3" value="-0.39" spread="0.417"/>
                    <measurement group_id="O4" value="-0.02" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.411"/>
                    <measurement group_id="O2" value="-0.11" spread="0.455"/>
                    <measurement group_id="O3" value="-0.34" spread="0.497"/>
                    <measurement group_id="O4" value="-0.05" spread="0.499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.483"/>
                    <measurement group_id="O2" value="-0.16" spread="0.387"/>
                    <measurement group_id="O3" value="-0.45" spread="0.355"/>
                    <measurement group_id="O4" value="-0.21" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.49"/>
                    <measurement group_id="O2" value="-0.19" spread="0.42"/>
                    <measurement group_id="O3" value="-0.51" spread="0.348"/>
                    <measurement group_id="O4" value="-0.14" spread="0.348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.394"/>
                    <measurement group_id="O2" value="-0.21" spread="0.362"/>
                    <measurement group_id="O3" value="-0.38" spread="0.447"/>
                    <measurement group_id="O4" value="-0.1" spread="0.428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.85"/>
                    <measurement group_id="O2" value="-0.8" spread="1.76"/>
                    <measurement group_id="O3" value="-0.2" spread="2.46"/>
                    <measurement group_id="O4" value="-0.8" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.15"/>
                    <measurement group_id="O2" value="-0.6" spread="1.81"/>
                    <measurement group_id="O3" value="0" spread="1.8"/>
                    <measurement group_id="O4" value="-1.3" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.16"/>
                    <measurement group_id="O2" value="-0.1" spread="2.2"/>
                    <measurement group_id="O3" value="0.4" spread="1.78"/>
                    <measurement group_id="O4" value="-0.8" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.39"/>
                    <measurement group_id="O2" value="-0.3" spread="2.39"/>
                    <measurement group_id="O3" value="0.2" spread="2.91"/>
                    <measurement group_id="O4" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="3.28"/>
                    <measurement group_id="O2" value="-0.6" spread="2.24"/>
                    <measurement group_id="O3" value="1.1" spread="2.18"/>
                    <measurement group_id="O4" value="-0.6" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.91"/>
                    <measurement group_id="O2" value="-0.3" spread="2.36"/>
                    <measurement group_id="O3" value="0.8" spread="2.66"/>
                    <measurement group_id="O4" value="0.5" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.1599"/>
                    <measurement group_id="O2" value="-0.086" spread="0.1415"/>
                    <measurement group_id="O3" value="-0.122" spread="0.1353"/>
                    <measurement group_id="O4" value="-0.087" spread="0.1489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week2; n=41,38,14,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.141" spread="0.181"/>
                    <measurement group_id="O2" value="-0.108" spread="0.1754"/>
                    <measurement group_id="O3" value="-0.081" spread="0.1194"/>
                    <measurement group_id="O4" value="-0.105" spread="0.1159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week4; n=41,39,14,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.151" spread="0.1666"/>
                    <measurement group_id="O2" value="-0.125" spread="0.1421"/>
                    <measurement group_id="O3" value="-0.077" spread="0.1669"/>
                    <measurement group_id="O4" value="-0.078" spread="0.1871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week6; n=41,38,13,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.171" spread="0.1939"/>
                    <measurement group_id="O2" value="-0.181" spread="0.1823"/>
                    <measurement group_id="O3" value="-0.121" spread="0.1549"/>
                    <measurement group_id="O4" value="-0.159" spread="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week8; n=40,39,13,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.169" spread="0.2025"/>
                    <measurement group_id="O2" value="-0.23" spread="0.1937"/>
                    <measurement group_id="O3" value="-0.112" spread="0.1563"/>
                    <measurement group_id="O4" value="-0.14" spread="0.167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic Phosphorus; Week12; n=37,35,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.172" spread="0.1708"/>
                    <measurement group_id="O2" value="-0.168" spread="0.2047"/>
                    <measurement group_id="O3" value="-0.117" spread="0.1123"/>
                    <measurement group_id="O4" value="-0.136" spread="0.1943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.996"/>
                    <measurement group_id="O2" value="0.04" spread="1.002"/>
                    <measurement group_id="O3" value="0.19" spread="1.287"/>
                    <measurement group_id="O4" value="-0.01" spread="1.188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week2; n=41, 38, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.012"/>
                    <measurement group_id="O2" value="-0.13" spread="1.05"/>
                    <measurement group_id="O3" value="0.08" spread="1.309"/>
                    <measurement group_id="O4" value="-0.12" spread="1.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week4; n=41, 39, 14, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.145"/>
                    <measurement group_id="O2" value="-0.4" spread="1.047"/>
                    <measurement group_id="O3" value="0.11" spread="1.436"/>
                    <measurement group_id="O4" value="-0.88" spread="1.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week6; n=41, 38, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="1.09"/>
                    <measurement group_id="O2" value="-0.29" spread="1.13"/>
                    <measurement group_id="O3" value="-0.39" spread="0.883"/>
                    <measurement group_id="O4" value="-1.02" spread="0.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week8; n=40, 39, 13, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="1.088"/>
                    <measurement group_id="O2" value="-0.46" spread="1.337"/>
                    <measurement group_id="O3" value="-0.07" spread="1.206"/>
                    <measurement group_id="O4" value="-0.85" spread="1.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week12; n=37, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.164"/>
                    <measurement group_id="O2" value="-0.31" spread="1.276"/>
                    <measurement group_id="O3" value="-0.11" spread="1.272"/>
                    <measurement group_id="O4" value="-0.64" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12</title>
        <description>Blood samples were collected for the measurement of Creatinine Clearance at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. It is estimated by Cockcroft-Gault Equation. Change from Baseline in the Creatinine Clearance values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1, 2, 4, 6, 8 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12</title>
          <description>Blood samples were collected for the measurement of Creatinine Clearance at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. It is estimated by Cockcroft-Gault Equation. Change from Baseline in the Creatinine Clearance values are summarized for each post-Baseline assessment until Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Milliliter per minute (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine Clearance; Week1; n=40, 39, 15, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="9.79"/>
                    <measurement group_id="O2" value="-2.1" spread="19.51"/>
                    <measurement group_id="O3" value="-9.5" spread="10.09"/>
                    <measurement group_id="O4" value="5.7" spread="10.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance; Week2; n=41, 38,14,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="13.48"/>
                    <measurement group_id="O2" value="4.7" spread="11.33"/>
                    <measurement group_id="O3" value="-9" spread="12.55"/>
                    <measurement group_id="O4" value="-1.8" spread="15.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance; Week4; n=41, 39,14,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="12.45"/>
                    <measurement group_id="O2" value="1.9" spread="14.72"/>
                    <measurement group_id="O3" value="-9.1" spread="13.42"/>
                    <measurement group_id="O4" value="4.5" spread="16.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance; Week6; n=41, 38,13,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="11.93"/>
                    <measurement group_id="O2" value="-0.7" spread="16.25"/>
                    <measurement group_id="O3" value="-19.1" spread="20.54"/>
                    <measurement group_id="O4" value="1.5" spread="13.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance; Week8; n=40, 39,13,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="10.49"/>
                    <measurement group_id="O2" value="3.4" spread="19.94"/>
                    <measurement group_id="O3" value="-17.8" spread="16.1"/>
                    <measurement group_id="O4" value="-3" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance; Week12; n=38,35,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="15.06"/>
                    <measurement group_id="O2" value="2.2" spread="17.27"/>
                    <measurement group_id="O3" value="-14.3" spread="16.99"/>
                    <measurement group_id="O4" value="1.2" spread="20.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12</title>
        <description>Urine samples were collected for urinalysis at Baseline, Weeks 2, 12, 18, 24, 48 and PT FU Weeks 4. Number of participants with shift from Baseline in urinalysis to normal (NL), abnormal (ANL) and missing (MIS) data up to Week 12 are summarized. Urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine leukocyte esterase test (ULET) for detecting WBC, urine nitrite (UNIT), urine occult blood (UOB) were performed with dipstick method. Urine microscopy (UM) is performed to detect bacteria (BAC), red blood cells (RBC) and white blood cells (WBC). Other urinalysis parameter included urine pH (UpH) and urine specific gravity (USG). Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0), Weeks 2 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12</title>
          <description>Urine samples were collected for urinalysis at Baseline, Weeks 2, 12, 18, 24, 48 and PT FU Weeks 4. Number of participants with shift from Baseline in urinalysis to normal (NL), abnormal (ANL) and missing (MIS) data up to Week 12 are summarized. Urine bilirubin (UBIL), urine glucose (UGLU), urine ketones (UKET), urine leukocyte esterase test (ULET) for detecting WBC, urine nitrite (UNIT), urine occult blood (UOB) were performed with dipstick method. Urine microscopy (UM) is performed to detect bacteria (BAC), red blood cells (RBC) and white blood cells (WBC). Other urinalysis parameter included urine pH (UpH) and urine specific gravity (USG). Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2, UBIL, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UBIL, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, UGLU, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UGLU, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, UKET, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UKET, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, ULET, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, ULET, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UMBT, BL MIS to PBL MIS,n=1,1,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UMRBC, BL MIS to PBL MIS,n=4,5,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UMWBC, BL MIS to PBL MIS, n=4,5,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, UNIT, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UNIT, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, UOB, BL MIS to PBL MIS, n=1,0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UOB, BL MIS to PBL MIS,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, UPH, BL NL to PBL NL, n=1, 0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UPH, BL NL to PBL NL, n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, UPH, BL NL to PBL ANL, n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, USG, BL NL to PBL NL, n=1, 0,0,0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, USG, BL NL to PBL NL, n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, USG, BL NL to PBL ANL,n=37,34,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12</title>
        <description>The ECG parameter heart rate was measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12</title>
          <description>The ECG parameter heart rate was measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG heart rate is summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, n=41, 40, 15, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="8.28"/>
                    <measurement group_id="O2" value="0.8" spread="8.49"/>
                    <measurement group_id="O3" value="4.1" spread="9.52"/>
                    <measurement group_id="O4" value="4.8" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="8.37"/>
                    <measurement group_id="O2" value="5.1" spread="10.86"/>
                    <measurement group_id="O3" value="9.3" spread="10.15"/>
                    <measurement group_id="O4" value="8.5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia’s Formula (QTcF) Values at the Indicated Time Points up to Week 12</title>
        <description>The ECG parameters including PR interval, QRS duration, uncorrected QT interval, QTcB, QTcF were measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG parameters are summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 1 and 12</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia’s Formula (QTcF) Values at the Indicated Time Points up to Week 12</title>
          <description>The ECG parameters including PR interval, QRS duration, uncorrected QT interval, QTcB, QTcF were measured at Baseline, Weeks 1 and 12. Change from Baseline in ECG parameters are summarized for each post-Baseline assessment up to Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval, Week 1, n=41, 40, 15, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="19.43"/>
                    <measurement group_id="O2" value="1.2" spread="13.57"/>
                    <measurement group_id="O3" value="2.7" spread="7.27"/>
                    <measurement group_id="O4" value="-1.6" spread="20.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval, Week 12, n=38, 35, 12, 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" spread="13.36"/>
                    <measurement group_id="O2" value="3.2" spread="12.07"/>
                    <measurement group_id="O3" value="5.5" spread="8.73"/>
                    <measurement group_id="O4" value="0.2" spread="14.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, Week 1, n=41, 40, 15,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="50.28"/>
                    <measurement group_id="O2" value="0.4" spread="7.69"/>
                    <measurement group_id="O3" value="2.9" spread="6.61"/>
                    <measurement group_id="O4" value="0.4" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS duration, Week 12, n=38, 35, 12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="51.69"/>
                    <measurement group_id="O2" value="-1.8" spread="6.44"/>
                    <measurement group_id="O3" value="0.4" spread="7.54"/>
                    <measurement group_id="O4" value="-2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT Interval, Week 1, n=41,40,15,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="27.29"/>
                    <measurement group_id="O2" value="-2.6" spread="22.29"/>
                    <measurement group_id="O3" value="-2.1" spread="22.39"/>
                    <measurement group_id="O4" value="5.9" spread="25.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncorrected QT interval, Week 12,n=38,35,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="31.28"/>
                    <measurement group_id="O2" value="-12" spread="25.22"/>
                    <measurement group_id="O3" value="-17" spread="18.01"/>
                    <measurement group_id="O4" value="-4.6" spread="23.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval, Week 1, n=41,40,15,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7087" spread="25.63001"/>
                    <measurement group_id="O2" value="0.2491" spread="22.90285"/>
                    <measurement group_id="O3" value="9.8112" spread="20.6771"/>
                    <measurement group_id="O4" value="19.8879" spread="40.13504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB interval, Week 12,n=38,35,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5512" spread="26.5644"/>
                    <measurement group_id="O2" value="1.7615" spread="20.3859"/>
                    <measurement group_id="O3" value="11.2801" spread="25.54652"/>
                    <measurement group_id="O4" value="18.9943" spread="16.76576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, Week 1, n=41,40,15,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1995" spread="23.18239"/>
                    <measurement group_id="O2" value="-0.7151" spread="19.69091"/>
                    <measurement group_id="O3" value="5.7676" spread="17.06472"/>
                    <measurement group_id="O4" value="14.9187" spread="32.2737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF interval, Week 12,n=38,35,12,13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3516" spread="26.34546"/>
                    <measurement group_id="O2" value="-3.1442" spread="17.38368"/>
                    <measurement group_id="O3" value="1.6147" spread="18.38188"/>
                    <measurement group_id="O4" value="10.7637" spread="17.07259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Any AEs and Any SAEs After Week 12</title>
        <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
        <time_frame>From Week 12 up to PT Week 24 FU</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any AEs and Any SAEs After Week 12</title>
          <description>An AE is defined as any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding), symptom, or disease(new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, a congenital anomaly/birth defect, important medical events that jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT)</title>
        <description>Blood samples for the determination of HCV RNA levels were collected at Screening and Baseline, every study visit during the Treatment Period, and at PT FU Weeks 4, 12, and 24. vRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 2 weeks after initiation of therapy. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. cEVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after initiation of therapy. SVR12 is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after completion of all therapy. SVR24 is defined as plasma HCV RNA &lt;LLOQ and target not detected 24 weeks after completion of all therapy. SVR24 with RGT are participants who achieved both SVR24 and eRVR.</description>
        <time_frame>From the start of the treatment up to PT FU Week 24</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT)</title>
          <description>Blood samples for the determination of HCV RNA levels were collected at Screening and Baseline, every study visit during the Treatment Period, and at PT FU Weeks 4, 12, and 24. vRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 2 weeks after initiation of therapy. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. cEVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after initiation of therapy. SVR12 is defined as plasma HCV RNA &lt;LLOQ and target not detected 12 weeks after completion of all therapy. SVR24 is defined as plasma HCV RNA &lt;LLOQ and target not detected 24 weeks after completion of all therapy. SVR24 with RGT are participants who achieved both SVR24 and eRVR.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>vRVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cEVR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24 with RGT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12</title>
        <description>Plasma pharmacokinetic (PK) samples were collected for all participants on Day 1 (0 hour [h]-1h, 1h-4h, 4h-8h, 8h-20h), Day 2 (Predose [20-28h]), Week 4 (Predose [20-28h], 0h-1h, 1h-4h, 4h-8h, 8h-20h, 20h-28h) and Week 12 (Predose [20-28h]). PK Population is comprised of all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study.</description>
        <time_frame>Day 1, Day 2, Week 4, and Week 12</time_frame>
        <population>PK Population included all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study. Only participants for whom plasma PK samples were obtained were assessed (represented by n=X, X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12</title>
          <description>Plasma pharmacokinetic (PK) samples were collected for all participants on Day 1 (0 hour [h]-1h, 1h-4h, 4h-8h, 8h-20h), Day 2 (Predose [20-28h]), Week 4 (Predose [20-28h], 0h-1h, 1h-4h, 4h-8h, 8h-20h, 20h-28h) and Week 12 (Predose [20-28h]). PK Population is comprised of all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study.</description>
          <population>PK Population included all participants who received GSK2336805 and underwent plasma PK sampling (intensive or sparse) during the study. Only participants for whom plasma PK samples were obtained were assessed (represented by n=X, X in category titles).</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 (0h-1h), n=1, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">A value of NA indicates not applicable</measurement>
                    <measurement group_id="O2" value="604" spread="392.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (1h-4h), n=35, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.39" spread="241.05"/>
                    <measurement group_id="O2" value="445.18" spread="314.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (4h-8h), n=0, 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O2" value="221.33" spread="191.996"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 (8h-20h), n=0, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O2" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 Predose (20-28h), n=36, 43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.79" spread="52.629"/>
                    <measurement group_id="O2" value="123.89" spread="257.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 Predose (20-28h), n=33, 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.18" spread="153.462"/>
                    <measurement group_id="O2" value="146.85" spread="243.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (0h-1h), n=2, 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.4" spread="242.679"/>
                    <measurement group_id="O2" value="553" spread="536.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (1h-4h), n=46, 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.78" spread="275.504"/>
                    <measurement group_id="O2" value="591.07" spread="402.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (4h-8h), n=22, 19</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.55" spread="127.737"/>
                    <measurement group_id="O2" value="411.68" spread="251.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (8h-20h), n=1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O2" value="192.5" spread="94.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (20h-28h), n=11, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.24" spread="57.261"/>
                    <measurement group_id="O2" value="66.29" spread="53.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (Predose [20-28h]), n=26, 35</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.99" spread="42.034"/>
                    <measurement group_id="O2" value="142.59" spread="178.252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4</title>
        <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours post-dose.</description>
        <time_frame>Week 4 (24 h post dose)</time_frame>
        <population>Intensive PK Summary Population: Intensive PK Summary Population comprised of participants with evaluable GSK2336805 PK parameters at Week 4. Only participants available at the indicated time point were assessed (represented by n=X, X in category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeksfollowed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 μg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4</title>
          <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours post-dose.</description>
          <population>Intensive PK Summary Population: Intensive PK Summary Population comprised of participants with evaluable GSK2336805 PK parameters at Week 4. Only participants available at the indicated time point were assessed (represented by n=X, X in category titles).</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax, n=11, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335.35" spread="69.4"/>
                    <measurement group_id="O2" value="618.75" spread="46.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau, n=11, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.37" spread="135.9"/>
                    <measurement group_id="O2" value="49.31" spread="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximal Plasma Concentration (Tmax) of GSK2336805 at Week 4</title>
        <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours postdose.</description>
        <time_frame>Week 4 (24 h post dose)</time_frame>
        <population>Intensive PK Summary Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 ug once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight is &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight is &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeksfollowed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 μg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight is &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight is &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximal Plasma Concentration (Tmax) of GSK2336805 at Week 4</title>
          <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7, 24 hours postdose.</description>
          <population>Intensive PK Summary Population</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) at Week 4</title>
        <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose.</description>
        <time_frame>Week 4 (24 h post dose)</time_frame>
        <population>Intensive PK Summary Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeksfollowed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 μg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) at Week 4</title>
          <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose.</description>
          <population>Intensive PK Summary Population</population>
          <units>hour*nanogram per milliliter(hr*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2733.34" spread="82"/>
                    <measurement group_id="O2" value="4948.23" spread="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F) at Week 4</title>
        <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. CL/F was calculated as dose divided by AUC(0-tau).</description>
        <time_frame>Week 4 (24 h post dose)</time_frame>
        <population>Intensive PK Summary Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeksfollowed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 μg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F) at Week 4</title>
          <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. CL/F was calculated as dose divided by AUC(0-tau).</description>
          <population>Intensive PK Summary Population</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.63" spread="82"/>
                    <measurement group_id="O2" value="12.13" spread="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F) at Week 4</title>
        <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. Vz/F was calculated as dose divided by (AUC[0-tau] lambda z) where lambda z is the terminal phase rate constant.</description>
        <time_frame>Week 4 (24 h post dose)</time_frame>
        <population>Intensive PK Summary Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2tablets) OD in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeksfollowed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was180 μg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if bodyweight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F) at Week 4</title>
          <description>Blood samples for PK analysis of GSK2336805 was obtained on Week 4+1 day at predose and at 1, 2, 4, 7 and 24 hours postdose. Vz/F was calculated as dose divided by (AUC[0-tau] lambda z) where lambda z is the terminal phase rate constant.</description>
          <population>Intensive PK Summary Population</population>
          <units>Liter per hour (L/hr)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.81" spread="76.6"/>
                    <measurement group_id="O2" value="125.09" spread="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT Week 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils platelet count and white blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count and white blood cell count at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT Week 4. Change from Baseline in the basophils, eosinophils, lymphocytes, total neutrophils platelet count and white blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Giga cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils; Week18; n=37, 33, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.0178"/>
                    <measurement group_id="O2" value="-0.01" spread="0.0194"/>
                    <measurement group_id="O3" value="-0.014" spread="0.0112"/>
                    <measurement group_id="O4" value="-0.012" spread="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week24; n=34, 32, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.0177"/>
                    <measurement group_id="O2" value="-0.01" spread="0.0166"/>
                    <measurement group_id="O3" value="-0.013" spread="0.0129"/>
                    <measurement group_id="O4" value="-0.013" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.018" spread="0.0142"/>
                    <measurement group_id="O2" value="-0.012" spread="0.0148"/>
                    <measurement group_id="O3" value="-0.02" spread="0"/>
                    <measurement group_id="O4" value="-0.02" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.0165"/>
                    <measurement group_id="O2" value="-0.006" spread="0.019"/>
                    <measurement group_id="O3" value="-0.02">A value of NA indicates not applicable</measurement>
                    <measurement group_id="O4" value="-0.01" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.015" spread="0.0242"/>
                    <measurement group_id="O2" value="-0.005" spread="0.0187"/>
                    <measurement group_id="O3" value="0" spread="0.0424"/>
                    <measurement group_id="O4" value="-0.015" spread="0.0071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; Week48; n=7, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.0214"/>
                    <measurement group_id="O2" value="-0.007" spread="0.0197"/>
                    <measurement group_id="O3" value="0.02">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0.005" spread="0.0071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils; PT Week4; n=32, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.007" spread="0.0162"/>
                    <measurement group_id="O2" value="-0.003" spread="0.0189"/>
                    <measurement group_id="O3" value="-0.001" spread="0.0181"/>
                    <measurement group_id="O4" value="-0.003" spread="0.0119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week18; n=37, 33, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.119" spread="0.1006"/>
                    <measurement group_id="O2" value="-0.127" spread="0.1207"/>
                    <measurement group_id="O3" value="-0.087" spread="0.0507"/>
                    <measurement group_id="O4" value="-0.068" spread="0.0746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week24; n=34, 32, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.128" spread="0.101"/>
                    <measurement group_id="O2" value="-0.131" spread="0.1103"/>
                    <measurement group_id="O3" value="-0.118" spread="0.0612"/>
                    <measurement group_id="O4" value="-0.041" spread="0.1003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.124" spread="0.0982"/>
                    <measurement group_id="O2" value="-0.116" spread="0.1117"/>
                    <measurement group_id="O3" value="-0.13" spread="0.0849"/>
                    <measurement group_id="O4" value="-0.04" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.081" spread="0.1459"/>
                    <measurement group_id="O2" value="-0.123" spread="0.1003"/>
                    <measurement group_id="O3" value="-0.06">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.05" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.105" spread="0.074"/>
                    <measurement group_id="O2" value="-0.1" spread="0.12"/>
                    <measurement group_id="O3" value="-0.02" spread="0.0424"/>
                    <measurement group_id="O4" value="-0.04" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; Week48; n=8, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.071" spread="0.0889"/>
                    <measurement group_id="O2" value="-0.11" spread="0.1223"/>
                    <measurement group_id="O3" value="0.13">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.05" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils; PT Week4; n=32, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.069" spread="0.0925"/>
                    <measurement group_id="O2" value="-0.085" spread="0.1208"/>
                    <measurement group_id="O3" value="-0.07" spread="0.0694"/>
                    <measurement group_id="O4" value="-0.018" spread="0.0808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week18; n=37, 33, 13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.081" spread="0.5533"/>
                    <measurement group_id="O2" value="-1.157" spread="0.5373"/>
                    <measurement group_id="O3" value="-0.999" spread="0.4672"/>
                    <measurement group_id="O4" value="-0.973" spread="0.5328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week24; n=34, 32, 12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.181" spread="0.4795"/>
                    <measurement group_id="O2" value="-1.092" spread="0.5598"/>
                    <measurement group_id="O3" value="-1.405" spread="0.5912"/>
                    <measurement group_id="O4" value="-1.057" spread="0.4832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.225" spread="0.7588"/>
                    <measurement group_id="O2" value="-1.085" spread="0.798"/>
                    <measurement group_id="O3" value="-1.905" spread="0.1768"/>
                    <measurement group_id="O4" value="-1.845" spread="0.2899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.267" spread="0.6828"/>
                    <measurement group_id="O2" value="-1.286" spread="0.8983"/>
                    <measurement group_id="O3" value="-1.97">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-1.92" spread="0.4808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.135" spread="0.8657"/>
                    <measurement group_id="O2" value="-1.22" spread="0.9909"/>
                    <measurement group_id="O3" value="-1.125" spread="1.0253"/>
                    <measurement group_id="O4" value="-1.93" spread="0.1414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; Week48; n=7, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.779" spread="1.0639"/>
                    <measurement group_id="O2" value="-1.4" spread="1.0384"/>
                    <measurement group_id="O3" value="0.09">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-2.2" spread="0.0424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes; PT Week4; n=32, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.681" spread="0.4594"/>
                    <measurement group_id="O2" value="-0.7" spread="0.6163"/>
                    <measurement group_id="O3" value="-0.756" spread="0.5874"/>
                    <measurement group_id="O4" value="-0.737" spread="0.5666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week18; n=37, 33, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.186" spread="0.1588"/>
                    <measurement group_id="O2" value="-0.141" spread="0.1339"/>
                    <measurement group_id="O3" value="-0.088" spread="0.1663"/>
                    <measurement group_id="O4" value="-0.143" spread="0.1776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week24; n=34, 32, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.206" spread="0.1692"/>
                    <measurement group_id="O2" value="-0.156" spread="0.1574"/>
                    <measurement group_id="O3" value="-0.151" spread="0.1474"/>
                    <measurement group_id="O4" value="-0.121" spread="0.1902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.151" spread="0.1655"/>
                    <measurement group_id="O2" value="-0.135" spread="0.091"/>
                    <measurement group_id="O3" value="-0.4" spread="0.3111"/>
                    <measurement group_id="O4" value="-0.06" spread="0.0141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.255" spread="0.1474"/>
                    <measurement group_id="O2" value="-0.18" spread="0.0987"/>
                    <measurement group_id="O3" value="-0.2">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0.015" spread="0.1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.184" spread="0.234"/>
                    <measurement group_id="O2" value="-0.093" spread="0.1743"/>
                    <measurement group_id="O3" value="-0.025" spread="0.2192"/>
                    <measurement group_id="O4" value="-0.01" spread="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; Week48; n=7, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" spread="0.1744"/>
                    <measurement group_id="O2" value="-0.147" spread="0.088"/>
                    <measurement group_id="O3" value="0.02">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.085" spread="0.1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes; PT Week4; n=32, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.047" spread="0.1773"/>
                    <measurement group_id="O2" value="-0.031" spread="0.165"/>
                    <measurement group_id="O3" value="0.032" spread="0.1543"/>
                    <measurement group_id="O4" value="-0.053" spread="0.1536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week18; n=37, 33,13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.702" spread="1.9136"/>
                    <measurement group_id="O2" value="-2.378" spread="1.6735"/>
                    <measurement group_id="O3" value="-1.652" spread="0.852"/>
                    <measurement group_id="O4" value="-1.463" spread="0.7174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week24; n=34, 32,12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.527" spread="1.9492"/>
                    <measurement group_id="O2" value="-2.187" spread="1.7758"/>
                    <measurement group_id="O3" value="-1.308" spread="0.7148"/>
                    <measurement group_id="O4" value="-1.3" spread="0.9956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week30; n=13, 10,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.402" spread="1.7954"/>
                    <measurement group_id="O2" value="-2.252" spread="2.3658"/>
                    <measurement group_id="O3" value="-2.24" spread="1.2869"/>
                    <measurement group_id="O4" value="-2.085" spread="0.1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week36; n=12, 7, 1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.503" spread="1.6709"/>
                    <measurement group_id="O2" value="-2.777" spread="2.4215"/>
                    <measurement group_id="O3" value="-1.61">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-1.63" spread="0.297"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week42; n=10, 6, 2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="2.0311"/>
                    <measurement group_id="O2" value="-3.085" spread="2.7313"/>
                    <measurement group_id="O3" value="-0.565" spread="0.7849"/>
                    <measurement group_id="O4" value="-1.815" spread="0.4455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; Week48; n=7, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.129" spread="2.2597"/>
                    <measurement group_id="O2" value="-2.488" spread="3.397"/>
                    <measurement group_id="O3" value="0.02">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-1.445" spread="0.4596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils; PT Week4; n=32, 34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.158" spread="1.8855"/>
                    <measurement group_id="O2" value="-0.808" spread="1.6104"/>
                    <measurement group_id="O3" value="-0.744" spread="1.1276"/>
                    <measurement group_id="O4" value="-0.671" spread="0.8001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week18; n=38, 34, 13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.7" spread="43.93"/>
                    <measurement group_id="O2" value="-87.5" spread="38.4"/>
                    <measurement group_id="O3" value="-55.7" spread="56.96"/>
                    <measurement group_id="O4" value="-52.1" spread="39.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week24; n=35, 33, 12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.5" spread="43.22"/>
                    <measurement group_id="O2" value="-78.8" spread="44.15"/>
                    <measurement group_id="O3" value="-60.3" spread="56.5"/>
                    <measurement group_id="O4" value="-51.9" spread="44.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week30; n=13, 10, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-70" spread="60.5"/>
                    <measurement group_id="O2" value="-71.9" spread="59.35"/>
                    <measurement group_id="O3" value="-112">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-36.5" spread="47.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.1" spread="41.52"/>
                    <measurement group_id="O2" value="-75.7" spread="65.89"/>
                    <measurement group_id="O3" value="-115">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-34" spread="52.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.1" spread="53.01"/>
                    <measurement group_id="O2" value="-67.3" spread="62.09"/>
                    <measurement group_id="O3" value="-112" spread="0"/>
                    <measurement group_id="O4" value="-22" spread="52.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; Week48; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.7" spread="66.18"/>
                    <measurement group_id="O2" value="-68.8" spread="65.74"/>
                    <measurement group_id="O3" value="33">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-14" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count; PT Week4; n=32, 34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.4" spread="44.37"/>
                    <measurement group_id="O2" value="-28.9" spread="45.92"/>
                    <measurement group_id="O3" value="-12.4" spread="34.3"/>
                    <measurement group_id="O4" value="-12.9" spread="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week18; n=37,33,13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="2.258"/>
                    <measurement group_id="O2" value="-3.81" spread="1.884"/>
                    <measurement group_id="O3" value="-2.84" spread="0.961"/>
                    <measurement group_id="O4" value="-2.65" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count ; Week24; n=34,32,12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.06" spread="2.251"/>
                    <measurement group_id="O2" value="-3.58" spread="1.977"/>
                    <measurement group_id="O3" value="-3" spread="1.047"/>
                    <measurement group_id="O4" value="-2.52" spread="1.272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count ; Week30; n=13,10,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="2.258"/>
                    <measurement group_id="O2" value="-3.59" spread="3.051"/>
                    <measurement group_id="O3" value="-4.7" spread="1.838"/>
                    <measurement group_id="O4" value="-4.05" spread="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count ; Week36; n=12,7,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.13" spread="2.188"/>
                    <measurement group_id="O2" value="-4.39" spread="3.168"/>
                    <measurement group_id="O3" value="-3.9">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-3.55" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count ; Week42; n=10,6,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.67" spread="2.807"/>
                    <measurement group_id="O2" value="-4.52" spread="3.68"/>
                    <measurement group_id="O3" value="-1.75" spread="2.051"/>
                    <measurement group_id="O4" value="-3.8" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; Week48; n=7,6,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="3.304"/>
                    <measurement group_id="O2" value="-4.17" spread="4.172"/>
                    <measurement group_id="O3" value="0.2">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-3.8" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count; PT Week4;n=32,34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.938"/>
                    <measurement group_id="O2" value="-1.64" spread="1.907"/>
                    <measurement group_id="O3" value="-1.54" spread="1.638"/>
                    <measurement group_id="O4" value="-1.45" spread="0.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of red blood cell count at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the red blood cell count values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Trillion cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red Blood Cell count; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.494"/>
                    <measurement group_id="O2" value="-0.88" spread="0.591"/>
                    <measurement group_id="O3" value="-1.19" spread="0.638"/>
                    <measurement group_id="O4" value="-0.99" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="0.482"/>
                    <measurement group_id="O2" value="-0.94" spread="0.513"/>
                    <measurement group_id="O3" value="-1.19" spread="0.552"/>
                    <measurement group_id="O4" value="-1.14" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week 30; n=13,10,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.511"/>
                    <measurement group_id="O2" value="-0.75" spread="0.809"/>
                    <measurement group_id="O3" value="-1.45" spread="0.071"/>
                    <measurement group_id="O4" value="-1.45" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week 36; n=12,7,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" spread="0.67"/>
                    <measurement group_id="O2" value="-1.06" spread="0.761"/>
                    <measurement group_id="O3" value="-1">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-1.3" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week 42; n=10,6,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.91" spread="0.674"/>
                    <measurement group_id="O2" value="-1.17" spread="0.769"/>
                    <measurement group_id="O3" value="-0.55" spread="0.636"/>
                    <measurement group_id="O4" value="-1.45" spread="0.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; Week 48; n=9, 6,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.791"/>
                    <measurement group_id="O2" value="-1.03" spread="0.794"/>
                    <measurement group_id="O3" value="-0.4">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-1.5" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count; PT Week 4; n=32,34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.435"/>
                    <measurement group_id="O2" value="-0.37" spread="0.353"/>
                    <measurement group_id="O3" value="-0.66" spread="0.437"/>
                    <measurement group_id="O4" value="-0.65" spread="0.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hemoglobin at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of hemoglobin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hemoglobin at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of hemoglobin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hemoglobin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.6" spread="12.34"/>
                    <measurement group_id="O2" value="-26.7" spread="14.65"/>
                    <measurement group_id="O3" value="-35" spread="16.38"/>
                    <measurement group_id="O4" value="-29" spread="10.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 24; n=35, 33, 12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.4" spread="12.16"/>
                    <measurement group_id="O2" value="-28" spread="12.44"/>
                    <measurement group_id="O3" value="-35.6" spread="13.48"/>
                    <measurement group_id="O4" value="-32.3" spread="14.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" spread="16.13"/>
                    <measurement group_id="O2" value="-21" spread="20.02"/>
                    <measurement group_id="O3" value="-40" spread="12.73"/>
                    <measurement group_id="O4" value="-40" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="18.86"/>
                    <measurement group_id="O2" value="-30" spread="16.37"/>
                    <measurement group_id="O3" value="-37">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-35" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.1" spread="18.51"/>
                    <measurement group_id="O2" value="-31.7" spread="19.82"/>
                    <measurement group_id="O3" value="-25" spread="22.63"/>
                    <measurement group_id="O4" value="-40" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; Week 48; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" spread="21.47"/>
                    <measurement group_id="O2" value="-29.3" spread="20.33"/>
                    <measurement group_id="O3" value="-18">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-41" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin; PT Week 4; n=32, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="11.43"/>
                    <measurement group_id="O2" value="-11.7" spread="9.57"/>
                    <measurement group_id="O3" value="-21.4" spread="8.59"/>
                    <measurement group_id="O4" value="-16.8" spread="11.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Hematocrit at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of hematocrit at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Hematocrit at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of hematocrit at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the hematocrit values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.083" spread="0.03831"/>
                    <measurement group_id="O2" value="-0.0622" spread="0.04289"/>
                    <measurement group_id="O3" value="-0.0776" spread="0.04313"/>
                    <measurement group_id="O4" value="-0.0699" spread="0.02801"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0782" spread="0.04021"/>
                    <measurement group_id="O2" value="-0.0635" spread="0.03499"/>
                    <measurement group_id="O3" value="-0.0808" spread="0.03543"/>
                    <measurement group_id="O4" value="-0.0823" spread="0.03968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 30; n=13, 10, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0713" spread="0.0486"/>
                    <measurement group_id="O2" value="-0.0397" spread="0.05793"/>
                    <measurement group_id="O3" value="-0.0955" spread="0.03323"/>
                    <measurement group_id="O4" value="-0.1125" spread="0.00636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 36; n=12, 7, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0567" spread="0.05031"/>
                    <measurement group_id="O2" value="-0.069" spread="0.04724"/>
                    <measurement group_id="O3" value="-0.087">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable).</measurement>
                    <measurement group_id="O4" value="-0.0895" spread="0.00354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 42; n=10, 6, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0623" spread="0.05449"/>
                    <measurement group_id="O2" value="-0.0802" spread="0.0562"/>
                    <measurement group_id="O3" value="-0.0535" spread="0.07"/>
                    <measurement group_id="O4" value="-0.111" spread="0.00566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; Week 48; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0624" spread="0.06203"/>
                    <measurement group_id="O2" value="-0.0753" spread="0.05285"/>
                    <measurement group_id="O3" value="-0.047">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable).</measurement>
                    <measurement group_id="O4" value="-0.1095" spread="0.03041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit; PT Week 4; n=32, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0293" spread="0.03575"/>
                    <measurement group_id="O2" value="-0.0135" spread="0.03178"/>
                    <measurement group_id="O3" value="-0.0362" spread="0.02907"/>
                    <measurement group_id="O4" value="-0.0354" spread="0.0358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of mean corpuscle volume at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of mean corpuscle volume at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the mean corpuscle volume values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Femtoliters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Corpuscle Volume ; Week 18;n=38,34,13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" spread="6.37"/>
                    <measurement group_id="O2" value="6.2" spread="8.19"/>
                    <measurement group_id="O3" value="8.5" spread="5.78"/>
                    <measurement group_id="O4" value="5.3" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume ; Week 24;n=35,33,12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="6.14"/>
                    <measurement group_id="O2" value="7.5" spread="8.89"/>
                    <measurement group_id="O3" value="7.6" spread="5.9"/>
                    <measurement group_id="O4" value="5.8" spread="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume ; Week 30; n=13,10,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.24"/>
                    <measurement group_id="O2" value="9.5" spread="12.02"/>
                    <measurement group_id="O3" value="11.5" spread="7.78"/>
                    <measurement group_id="O4" value="3" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume ; Week 36; n=12,7,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.92"/>
                    <measurement group_id="O2" value="11.4" spread="13.6"/>
                    <measurement group_id="O3" value="2">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="5.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume ; Week 42;n=10,6,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="5.7"/>
                    <measurement group_id="O2" value="10.7" spread="14.47"/>
                    <measurement group_id="O3" value="1" spread="2.83"/>
                    <measurement group_id="O4" value="4" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume ; Week 48;n=9,6,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.76"/>
                    <measurement group_id="O2" value="9" spread="14.04"/>
                    <measurement group_id="O3" value="-1">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="5" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume; PT Week 4; n=32,34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="5.56"/>
                    <measurement group_id="O2" value="5.1" spread="4.86"/>
                    <measurement group_id="O3" value="5.8" spread="3.79"/>
                    <measurement group_id="O4" value="5.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Albumin at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of albumin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Albumin at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of albumin at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the albumin values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="2.78"/>
                    <measurement group_id="O2" value="-1.4" spread="2.65"/>
                    <measurement group_id="O3" value="-1.8" spread="2.86"/>
                    <measurement group_id="O4" value="-1" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.08"/>
                    <measurement group_id="O2" value="-1.6" spread="2.82"/>
                    <measurement group_id="O3" value="-2.3" spread="2.81"/>
                    <measurement group_id="O4" value="-1.1" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="2.09"/>
                    <measurement group_id="O2" value="-0.7" spread="4.22"/>
                    <measurement group_id="O3" value="-3" spread="2.65"/>
                    <measurement group_id="O4" value="-4.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="3.92"/>
                    <measurement group_id="O2" value="-1.1" spread="2.85"/>
                    <measurement group_id="O3" value="2" spread="1.41"/>
                    <measurement group_id="O4" value="-2" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.5"/>
                    <measurement group_id="O2" value="-1.3" spread="1.63"/>
                    <measurement group_id="O3" value="-1">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.61"/>
                    <measurement group_id="O2" value="-0.3" spread="2.16"/>
                    <measurement group_id="O3" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-4" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.93"/>
                    <measurement group_id="O2" value="-0.2" spread="2.84"/>
                    <measurement group_id="O3" value="0.5" spread="2.3"/>
                    <measurement group_id="O4" value="-0.7" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ALP, ALT, AST, CK and GGT at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight is &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ALP, ALT, AST, CK and GGT at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of ALP, ALT, AST, CK and GGT at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the ALP, ALT, AST, CK and GGT values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>International units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALP; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="17.25"/>
                    <measurement group_id="O2" value="1.1" spread="16.95"/>
                    <measurement group_id="O3" value="2.2" spread="21.77"/>
                    <measurement group_id="O4" value="6.4" spread="20.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="19.71"/>
                    <measurement group_id="O2" value="3.3" spread="18.83"/>
                    <measurement group_id="O3" value="2.1" spread="20.24"/>
                    <measurement group_id="O4" value="4.5" spread="22.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="15.79"/>
                    <measurement group_id="O2" value="-6.4" spread="18.62"/>
                    <measurement group_id="O3" value="-8" spread="8.54"/>
                    <measurement group_id="O4" value="22.5" spread="14.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="17.49"/>
                    <measurement group_id="O2" value="2.7" spread="9.45"/>
                    <measurement group_id="O3" value="2.5" spread="0.71"/>
                    <measurement group_id="O4" value="18" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="13.4"/>
                    <measurement group_id="O2" value="3.3" spread="8.45"/>
                    <measurement group_id="O3" value="-2">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="17.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" spread="17.36"/>
                    <measurement group_id="O2" value="4.2" spread="9.62"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="30" spread="24.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="19.71"/>
                    <measurement group_id="O2" value="-6.3" spread="17.88"/>
                    <measurement group_id="O3" value="-7" spread="17.93"/>
                    <measurement group_id="O4" value="-3.9" spread="22.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.9" spread="61.39"/>
                    <measurement group_id="O2" value="-22.9" spread="61.65"/>
                    <measurement group_id="O3" value="-38.6" spread="40.89"/>
                    <measurement group_id="O4" value="-38.4" spread="32.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.9" spread="62.25"/>
                    <measurement group_id="O2" value="-31.3" spread="56.12"/>
                    <measurement group_id="O3" value="-39.7" spread="38.19"/>
                    <measurement group_id="O4" value="-41.7" spread="28.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" spread="30.82"/>
                    <measurement group_id="O2" value="-45.1" spread="95.76"/>
                    <measurement group_id="O3" value="-57.7" spread="58.31"/>
                    <measurement group_id="O4" value="-26" spread="22.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.2" spread="28.15"/>
                    <measurement group_id="O2" value="-16.6" spread="13.7"/>
                    <measurement group_id="O3" value="-69" spread="74.95"/>
                    <measurement group_id="O4" value="-20.5" spread="16.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.3" spread="35.15"/>
                    <measurement group_id="O2" value="-14.3" spread="20.07"/>
                    <measurement group_id="O3" value="-122">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-28" spread="25.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.8" spread="42.1"/>
                    <measurement group_id="O2" value="-10.8" spread="27.11"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-26.5" spread="26.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.5" spread="62.76"/>
                    <measurement group_id="O2" value="-33.3" spread="56.81"/>
                    <measurement group_id="O3" value="-31.5" spread="22.68"/>
                    <measurement group_id="O4" value="-43.9" spread="27.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.1" spread="27.49"/>
                    <measurement group_id="O2" value="-3.5" spread="37.25"/>
                    <measurement group_id="O3" value="-18.8" spread="27.32"/>
                    <measurement group_id="O4" value="-16.3" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="26.86"/>
                    <measurement group_id="O2" value="-11.8" spread="30.51"/>
                    <measurement group_id="O3" value="-23.8" spread="26.91"/>
                    <measurement group_id="O4" value="-15.7" spread="18.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.1" spread="17.35"/>
                    <measurement group_id="O2" value="-18.7" spread="43.89"/>
                    <measurement group_id="O3" value="-27.7" spread="20.13"/>
                    <measurement group_id="O4" value="-6.5" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="13.81"/>
                    <measurement group_id="O2" value="-7.3" spread="9.5"/>
                    <measurement group_id="O3" value="-27.5" spread="31.82"/>
                    <measurement group_id="O4" value="-2.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" spread="16.81"/>
                    <measurement group_id="O2" value="-5.8" spread="10.03"/>
                    <measurement group_id="O3" value="-54">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-9" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="18.65"/>
                    <measurement group_id="O2" value="-2.2" spread="13.61"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-6.5" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.5" spread="26.41"/>
                    <measurement group_id="O2" value="-15.6" spread="34.38"/>
                    <measurement group_id="O3" value="-17.7" spread="14.67"/>
                    <measurement group_id="O4" value="-16" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44" spread="55.77"/>
                    <measurement group_id="O2" value="-28.3" spread="36.59"/>
                    <measurement group_id="O3" value="-38.7" spread="45.46"/>
                    <measurement group_id="O4" value="-60.7" spread="75.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.5" spread="66.48"/>
                    <measurement group_id="O2" value="-18.7" spread="77.24"/>
                    <measurement group_id="O3" value="-39" spread="36.68"/>
                    <measurement group_id="O4" value="60.1" spread="475.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33" spread="83.25"/>
                    <measurement group_id="O2" value="-15.8" spread="51.92"/>
                    <measurement group_id="O3" value="-30" spread="24.27"/>
                    <measurement group_id="O4" value="-78.5" spread="55.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" spread="34.18"/>
                    <measurement group_id="O2" value="-26.7" spread="32.22"/>
                    <measurement group_id="O3" value="-37.5" spread="6.36"/>
                    <measurement group_id="O4" value="-69" spread="53.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="51.5"/>
                    <measurement group_id="O2" value="-29.7" spread="43.42"/>
                    <measurement group_id="O3" value="-32">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-81" spread="57.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="71.39"/>
                    <measurement group_id="O2" value="22.3" spread="77.32"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-82.5" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="48.82"/>
                    <measurement group_id="O2" value="-26.4" spread="49.42"/>
                    <measurement group_id="O3" value="-21.7" spread="42.62"/>
                    <measurement group_id="O4" value="258.7" spread="994.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.3" spread="71.19"/>
                    <measurement group_id="O2" value="-12.3" spread="60.35"/>
                    <measurement group_id="O3" value="-30.2" spread="42.04"/>
                    <measurement group_id="O4" value="-34.2" spread="56.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.3" spread="72.79"/>
                    <measurement group_id="O2" value="-12.5" spread="86.73"/>
                    <measurement group_id="O3" value="-37.4" spread="45.44"/>
                    <measurement group_id="O4" value="-35.7" spread="59.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.2" spread="41.3"/>
                    <measurement group_id="O2" value="-32.8" spread="31.81"/>
                    <measurement group_id="O3" value="-38.7" spread="36.02"/>
                    <measurement group_id="O4" value="-12" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.5" spread="45.03"/>
                    <measurement group_id="O2" value="-19.7" spread="24.52"/>
                    <measurement group_id="O3" value="-40.5" spread="33.23"/>
                    <measurement group_id="O4" value="-10" spread="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.6" spread="46.61"/>
                    <measurement group_id="O2" value="-19.7" spread="25.06"/>
                    <measurement group_id="O3" value="-17">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-9" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.8" spread="28.74"/>
                    <measurement group_id="O2" value="-16.8" spread="24.38"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-9.5" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-43.4" spread="78.29"/>
                    <measurement group_id="O2" value="-17.7" spread="78.22"/>
                    <measurement group_id="O3" value="-30.7" spread="41.91"/>
                    <measurement group_id="O4" value="-41.4" spread="61.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Total Bilirubin and Creatinine at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of total bilirubin and creatinine at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment afterl Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Total Bilirubin and Creatinine at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of total bilirubin and creatinine at the the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Week 4. Change from Baseline in the direct bilirubin, total bilirubin and creatinine values are summarized for each post-Baseline assessment afterl Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Micromoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total bilirubin; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.01"/>
                    <measurement group_id="O2" value="1.7" spread="5.32"/>
                    <measurement group_id="O3" value="-1.4" spread="11.37"/>
                    <measurement group_id="O4" value="0.6" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Week 24; n=35, 33, 12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.73"/>
                    <measurement group_id="O2" value="1" spread="4.08"/>
                    <measurement group_id="O3" value="-1.3" spread="11.9"/>
                    <measurement group_id="O4" value="1.3" spread="6.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="5.99"/>
                    <measurement group_id="O2" value="0.8" spread="4.76"/>
                    <measurement group_id="O3" value="-2.3" spread="9.29"/>
                    <measurement group_id="O4" value="-4" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="4.29"/>
                    <measurement group_id="O2" value="1.9" spread="4.95"/>
                    <measurement group_id="O3" value="-3" spread="11.31"/>
                    <measurement group_id="O4" value="-3" spread="7.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.11"/>
                    <measurement group_id="O2" value="1.5" spread="5.79"/>
                    <measurement group_id="O3" value="-14">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-4" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="4.72"/>
                    <measurement group_id="O2" value="3.5" spread="7.2"/>
                    <measurement group_id="O3" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-4" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin PT Week 4; n=33, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="3.57"/>
                    <measurement group_id="O2" value="-2.4" spread="3.3"/>
                    <measurement group_id="O3" value="-0.4" spread="5.68"/>
                    <measurement group_id="O4" value="-2.2" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.55" spread="9.507"/>
                    <measurement group_id="O2" value="-2.4" spread="8.413"/>
                    <measurement group_id="O3" value="-3.12" spread="9.408"/>
                    <measurement group_id="O4" value="1.31" spread="10.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="9.186"/>
                    <measurement group_id="O2" value="-1.97" spread="9.65"/>
                    <measurement group_id="O3" value="-1.75" spread="9.874"/>
                    <measurement group_id="O4" value="0.09" spread="10.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="4.603"/>
                    <measurement group_id="O2" value="2.82" spread="8.123"/>
                    <measurement group_id="O3" value="-8.47" spread="8.693"/>
                    <measurement group_id="O4" value="-8.85" spread="3.748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="11.096"/>
                    <measurement group_id="O2" value="2.99" spread="8.179"/>
                    <measurement group_id="O3" value="-5.5" spread="16.829"/>
                    <measurement group_id="O4" value="-8" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="10.32"/>
                    <measurement group_id="O2" value="4.97" spread="11.697"/>
                    <measurement group_id="O3" value="-14.3">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-7.55" spread="5.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="4.222"/>
                    <measurement group_id="O2" value="10.07" spread="17.173"/>
                    <measurement group_id="O3" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-7.1" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine; PT Week 4; n=33, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" spread="8.22"/>
                    <measurement group_id="O2" value="-0.34" spread="7.624"/>
                    <measurement group_id="O3" value="-1.7" spread="6.897"/>
                    <measurement group_id="O4" value="-1.25" spread="6.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in SBP and DBP at the Indicated Time Points After Week 12</title>
        <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in SBP and DBP at the Indicated Time Points After Week 12</title>
          <description>Blood pressure measurements were taken to observe vital signs and included SBP and DBP at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
          <population>Safety Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Heart Rate at the Indicated Time Points After Week 12</title>
        <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from Baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Heart Rate at the Indicated Time Points After Week 12</title>
          <description>Vital sign monitoring included heart rate, measured at the Baseline, Day 2, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. As defined in the Reporting Analysis Plan (RAP) for this protocol, the supplemental final data package generated for this study after Week 12 only provided graphical displays of vital signs (e.g., change from Baseline for heart rate and blood pressure) to facilitate clinical interpretation and data summarization. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed. All abnormal values and statistical summary tables were not available after week 12.</description>
          <population>Safety Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in ECG Heart Rate Values at the Indicated Time Points After Week 12</title>
        <description>The ECG data was only collected “Perform as needed”, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in ECG Heart Rate Values at the Indicated Time Points After Week 12</title>
          <description>The ECG data was only collected “Perform as needed”, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QTcB, QTcF Values at the Indicated Time Points After Week 12</title>
        <description>The ECG data was only collected “Perform as needed”, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval, QTcB, QTcF Values at the Indicated Time Points After Week 12</title>
          <description>The ECG data was only collected “Perform as needed”, therefore, no such summary table was generated. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/BUN at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/bun at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Bun values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/BUN at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of Chloride, bicarbonate, glucose, potassium, sodium, inorganic phosphorus and urea/bun at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Bun values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>Millimoles per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chloride; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.75"/>
                    <measurement group_id="O2" value="1" spread="2.5"/>
                    <measurement group_id="O3" value="1.8" spread="2.41"/>
                    <measurement group_id="O4" value="0.5" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.33"/>
                    <measurement group_id="O2" value="0.7" spread="2.73"/>
                    <measurement group_id="O3" value="2.9" spread="2.81"/>
                    <measurement group_id="O4" value="-0.2" spread="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.72"/>
                    <measurement group_id="O2" value="0.3" spread="2.87"/>
                    <measurement group_id="O3" value="5.3" spread="3.21"/>
                    <measurement group_id="O4" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.11"/>
                    <measurement group_id="O2" value="-0.1" spread="2.54"/>
                    <measurement group_id="O3" value="4.5" spread="6.36"/>
                    <measurement group_id="O4" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.78"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                    <measurement group_id="O3" value="10">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.34"/>
                    <measurement group_id="O2" value="-1" spread="3.16"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.69"/>
                    <measurement group_id="O2" value="0.2" spread="2.54"/>
                    <measurement group_id="O3" value="0.6" spread="2.29"/>
                    <measurement group_id="O4" value="-1.5" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 18; n=38, 34, 13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.18"/>
                    <measurement group_id="O2" value="-1" spread="2.16"/>
                    <measurement group_id="O3" value="-1.2" spread="2.27"/>
                    <measurement group_id="O4" value="0" spread="2.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 24; n=35, 33, 12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2.41"/>
                    <measurement group_id="O2" value="-1.2" spread="2.21"/>
                    <measurement group_id="O3" value="-1.8" spread="2.41"/>
                    <measurement group_id="O4" value="-0.4" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.33"/>
                    <measurement group_id="O2" value="-2.2" spread="4.02"/>
                    <measurement group_id="O3" value="-1.3" spread="1.53"/>
                    <measurement group_id="O4" value="-2" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.92"/>
                    <measurement group_id="O2" value="0.1" spread="1.86"/>
                    <measurement group_id="O3" value="-2.5" spread="2.12"/>
                    <measurement group_id="O4" value="-1.5" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.73"/>
                    <measurement group_id="O2" value="-0.2" spread="2.04"/>
                    <measurement group_id="O3" value="-4">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-1" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.67"/>
                    <measurement group_id="O2" value="-1.3" spread="2.66"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.5" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate; PT Week 4; n=33, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="2.1"/>
                    <measurement group_id="O2" value="-0.5" spread="2.46"/>
                    <measurement group_id="O3" value="-0.9" spread="2.43"/>
                    <measurement group_id="O4" value="1" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.326"/>
                    <measurement group_id="O2" value="-0.13" spread="1.188"/>
                    <measurement group_id="O3" value="-0.06" spread="0.702"/>
                    <measurement group_id="O4" value="-0.23" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="1.552"/>
                    <measurement group_id="O2" value="0.27" spread="2.986"/>
                    <measurement group_id="O3" value="-0.23" spread="0.672"/>
                    <measurement group_id="O4" value="-0.22" spread="1.349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="1.383"/>
                    <measurement group_id="O2" value="-0.26" spread="0.587"/>
                    <measurement group_id="O3" value="-0.13" spread="0.252"/>
                    <measurement group_id="O4" value="0.9" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.758"/>
                    <measurement group_id="O2" value="-0.37" spread="1.09"/>
                    <measurement group_id="O3" value="-0.1" spread="0.99"/>
                    <measurement group_id="O4" value="-0.7" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="1.663"/>
                    <measurement group_id="O2" value="-0.12" spread="0.794"/>
                    <measurement group_id="O3" value="0.4">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.15" spread="0.919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="1.358"/>
                    <measurement group_id="O2" value="-0.3" spread="0.867"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="4.55" spread="4.596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="3.122"/>
                    <measurement group_id="O2" value="0.18" spread="0.684"/>
                    <measurement group_id="O3" value="-0.12" spread="0.735"/>
                    <measurement group_id="O4" value="-0.07" spread="1.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.399"/>
                    <measurement group_id="O2" value="-0.24" spread="0.376"/>
                    <measurement group_id="O3" value="-0.41" spread="0.236"/>
                    <measurement group_id="O4" value="-0.2" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.452"/>
                    <measurement group_id="O2" value="-0.12" spread="0.459"/>
                    <measurement group_id="O3" value="-0.34" spread="0.403"/>
                    <measurement group_id="O4" value="-0.32" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.48"/>
                    <measurement group_id="O2" value="-0.23" spread="0.377"/>
                    <measurement group_id="O3" value="-0.1" spread="0.2"/>
                    <measurement group_id="O4" value="-0.1" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.599"/>
                    <measurement group_id="O2" value="-0.1" spread="0.365"/>
                    <measurement group_id="O3" value="0.15" spread="0.071"/>
                    <measurement group_id="O4" value="0.2" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.555"/>
                    <measurement group_id="O2" value="-0.2" spread="0.415"/>
                    <measurement group_id="O3" value="-0.1">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0.1" spread="0.566"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.566"/>
                    <measurement group_id="O2" value="-0.3" spread="0.322"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="0.05" spread="0.495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium; PT Week 4; n=33, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.382"/>
                    <measurement group_id="O2" value="-0.13" spread="0.398"/>
                    <measurement group_id="O3" value="-0.25" spread="0.532"/>
                    <measurement group_id="O4" value="-0.1" spread="0.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.04"/>
                    <measurement group_id="O2" value="0.1" spread="2.27"/>
                    <measurement group_id="O3" value="0.7" spread="2.32"/>
                    <measurement group_id="O4" value="0.4" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.86"/>
                    <measurement group_id="O2" value="-0.1" spread="2.61"/>
                    <measurement group_id="O3" value="1.5" spread="2.24"/>
                    <measurement group_id="O4" value="0.4" spread="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="3.25"/>
                    <measurement group_id="O2" value="-1.4" spread="2.72"/>
                    <measurement group_id="O3" value="1.3" spread="1.53"/>
                    <measurement group_id="O4" value="0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.67"/>
                    <measurement group_id="O2" value="-0.7" spread="1.98"/>
                    <measurement group_id="O3" value="2" spread="2.83"/>
                    <measurement group_id="O4" value="-0.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.07"/>
                    <measurement group_id="O2" value="-0.5" spread="1.38"/>
                    <measurement group_id="O3" value="3">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-1.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.14"/>
                    <measurement group_id="O2" value="-1.2" spread="2.79"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-2.5" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium; PT Week 4; n=33, 34, 11, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.3"/>
                    <measurement group_id="O2" value="0.1" spread="2.45"/>
                    <measurement group_id="O3" value="1.1" spread="2.47"/>
                    <measurement group_id="O4" value="-0.5" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 18; n=38,34,13,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.161" spread="0.1971"/>
                    <measurement group_id="O2" value="-0.13" spread="0.1928"/>
                    <measurement group_id="O3" value="-0.092" spread="0.1537"/>
                    <measurement group_id="O4" value="-0.111" spread="0.2648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 24; n=35,33,12,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.139" spread="0.2268"/>
                    <measurement group_id="O2" value="-0.13" spread="0.2354"/>
                    <measurement group_id="O3" value="-0.119" spread="0.1991"/>
                    <measurement group_id="O4" value="-0.107" spread="0.2205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 30; n=13,10,3,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.156" spread="0.1644"/>
                    <measurement group_id="O2" value="-0.118" spread="0.2071"/>
                    <measurement group_id="O3" value="-0.267" spread="0.2023"/>
                    <measurement group_id="O4" value="-0.225" spread="0.1768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 36; n=10,7,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.121" spread="0.2564"/>
                    <measurement group_id="O2" value="-0.167" spread="0.1906"/>
                    <measurement group_id="O3" value="-0.195" spread="0.0495"/>
                    <measurement group_id="O4" value="-0.125" spread="0.2475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 42; n=9,6,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.2248"/>
                    <measurement group_id="O2" value="-0.108" spread="0.0794"/>
                    <measurement group_id="O3" value="-0.15">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.1" spread="0.3536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; Week 48; n=6,6,0,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.167" spread="0.1715"/>
                    <measurement group_id="O2" value="-0.108" spread="0.1665"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.35" spread="0.0707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inorganic phosphorus; PT Week 4;n=33,34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.084" spread="0.2375"/>
                    <measurement group_id="O2" value="-0.003" spread="0.2162"/>
                    <measurement group_id="O3" value="0.009" spread="0.0798"/>
                    <measurement group_id="O4" value="-0.085" spread="0.2247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="1.166"/>
                    <measurement group_id="O2" value="-0.23" spread="1.403"/>
                    <measurement group_id="O3" value="-0.49" spread="1.233"/>
                    <measurement group_id="O4" value="-0.25" spread="1.688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="1.263"/>
                    <measurement group_id="O2" value="-0.55" spread="1.252"/>
                    <measurement group_id="O3" value="-0.43" spread="1.106"/>
                    <measurement group_id="O4" value="0.02" spread="2.007"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 30; n=13, 10, 3, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.107"/>
                    <measurement group_id="O2" value="-0.16" spread="1.027"/>
                    <measurement group_id="O3" value="-0.5" spread="1.082"/>
                    <measurement group_id="O4" value="-0.5" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 36; n=10, 7, 2, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="1.775"/>
                    <measurement group_id="O2" value="0.04" spread="1.172"/>
                    <measurement group_id="O3" value="-0.15" spread="0.636"/>
                    <measurement group_id="O4" value="-0.25" spread="1.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 42; n=9, 6, 1, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="1.65"/>
                    <measurement group_id="O2" value="0.5" spread="1.239"/>
                    <measurement group_id="O3" value="0.5">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.5" spread="1.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; Week 48; n=6, 6, 0, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.353"/>
                    <measurement group_id="O2" value="0.4" spread="1.607"/>
                    <measurement group_id="O3" value="NA">System value of NA indicates not applicable (too few participants).</measurement>
                    <measurement group_id="O4" value="-0.5" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN; PT Week 4; n=33, 34, 11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="1.284"/>
                    <measurement group_id="O2" value="-0.19" spread="1.311"/>
                    <measurement group_id="O3" value="-0.62" spread="1.012"/>
                    <measurement group_id="O4" value="-0.47" spread="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points After Week 12</title>
        <description>Blood samples were collected for the measurement of estimated creatinine clearance by Cockcroft-Gault formula at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the estimated creatinine clearance values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
        <time_frame>Baseline (Week 0) and Weeks 18, 24, 30, 36, 42, 48 and PT FU Week 4</time_frame>
        <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O3">
            <title>Telaprevir, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
          <group group_id="O4">
            <title>GSK2336805 60 mg, Genotype 4 HCV</title>
            <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points After Week 12</title>
          <description>Blood samples were collected for the measurement of estimated creatinine clearance by Cockcroft-Gault formula at the Baseline, Weeks 1, 2, 4, 6, 8, 12, 18, 24, 30, 36, 42, 48 and PT FU Weeks 4. Change from Baseline in the estimated creatinine clearance values are summarized for each post-Baseline assessment after Week 12. Change from Baseline was calculated as the individual post-Baseline value minus the Baseline value. Baseline value is defined as the last Pre-treatment value observed.</description>
          <population>Safety Population. Only those participants available at the specified time points were analyzed (represented by n=X,X,X,X in the category titles). Different participants may have been analyzed at different time points, so the overall number of participants analyzed reflects everyone in the safety population.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine clearance; Week 18; n=38, 34, 13, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="17.36"/>
                    <measurement group_id="O2" value="-1.1" spread="20.69"/>
                    <measurement group_id="O3" value="-2.5" spread="16.25"/>
                    <measurement group_id="O4" value="-4.3" spread="19.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; Week 24; n=35, 33, 12, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="16.77"/>
                    <measurement group_id="O2" value="-1" spread="18.53"/>
                    <measurement group_id="O3" value="-4.1" spread="15.11"/>
                    <measurement group_id="O4" value="-6.1" spread="19.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; Week 30; n=13,10,3,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="13.91"/>
                    <measurement group_id="O2" value="-10.4" spread="14.41"/>
                    <measurement group_id="O3" value="-3.7" spread="13.58"/>
                    <measurement group_id="O4" value="7" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; Week 36; n=10,7,2,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="23.3"/>
                    <measurement group_id="O2" value="-8.1" spread="13.28"/>
                    <measurement group_id="O3" value="-1" spread="29.7"/>
                    <measurement group_id="O4" value="1.5" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; Week 42; n=9, 6,1,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="16.86"/>
                    <measurement group_id="O2" value="-13.3" spread="16.13"/>
                    <measurement group_id="O3" value="9">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-1.5" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; Week 48; n=6, 6,0,2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="10.23"/>
                    <measurement group_id="O2" value="-15.8" spread="16.18"/>
                    <measurement group_id="O3" value="NA">The mean and standard deviation could not be determined (not reached) because too few participants experienced the event (system value of NA indicates not applicable for the mean and the standard deviation).</measurement>
                    <measurement group_id="O4" value="-4" spread="11.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance; PT Week 4; n=33,34,11,11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="34.53"/>
                    <measurement group_id="O2" value="-1.3" spread="23.85"/>
                    <measurement group_id="O3" value="-2.7" spread="11.38"/>
                    <measurement group_id="O4" value="-5.3" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus eRVR Status</title>
        <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (eRVR and no eRVE) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected pharmacokinetic parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>Intensive PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus eRVR Status</title>
          <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (eRVR and no eRVE) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected pharmacokinetic parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>Intensive PK Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus eRVR Status</title>
        <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus eRVR status (eRVR and no eRVR) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>Intensive PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus eRVR Status</title>
          <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus eRVR status (eRVR and no eRVR) was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>Intensive PK Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus RVR Status</title>
        <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (RVR and no eVE) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Week 4</time_frame>
        <population>Intensive PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 and G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma AUC(0-tau) Versus RVR Status</title>
          <description>Correlation of individual GSK2336805 40 mg and 60 mg with Week 4 plasma AUC(0-tau) versus eRVR Status (RVR and no eVE) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. AUC (0-tau) is area under the concentration-time curve over the dosing interval. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>Intensive PK Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus RVR Status</title>
        <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus RVR status (RVR and no RVR) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Week 4</time_frame>
        <population>Intensive PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Individual GSK2336805 Dose With Week 4 Plasma Cmax, Ctau, C0 Versus RVR Status</title>
          <description>Correlation of Individual GSK2336805 40 mg and 60 mg dose with Week 4 maximum plasma concentration (Cmax), pre-dose concentration (C0), concentration at the end of the dosing interval (Ctau) versus RVR status (RVR and no RVR) was performed. RVR is defined as plasma HCV RNA &lt;LLOQ and target not detected 4 weeks after initiation of therapy. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>Intensive PK Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Individual GSK2336805 Dose With Pre-dose Plasma Concentration at Week 4 and Week 12 Versus eRVR Status</title>
        <description>Correlation of individual GSK2336805 dose with pre-dose plasma concentration at Week 4 and Week 12 versus eRVR status was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. The PK/Pharmacodynamic (PD) analysis population comprised of all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable GSK2336805 plasma concentration data considered suitable for investigation of relationship with the PD measures. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>PK/PD Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 ug once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Individual GSK2336805 Dose With Pre-dose Plasma Concentration at Week 4 and Week 12 Versus eRVR Status</title>
          <description>Correlation of individual GSK2336805 dose with pre-dose plasma concentration at Week 4 and Week 12 versus eRVR status was performed. eRVR is defined as plasma HCV RNA &lt;LLOQ and target not detected at Weeks 4 and 12. The PK/Pharmacodynamic (PD) analysis population comprised of all participants with available PD measures (e.g., safety and/or efficacy data) and with evaluable GSK2336805 plasma concentration data considered suitable for investigation of relationship with the PD measures. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>PK/PD Analysis Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation GSK2336805 Pre-dose Plasma Concentration on Day 2 Versus Reduction in HCV RNA on Day 2</title>
        <description>Correlation GSK2336805 pre-dose plasma concentration (ng/mL) on Day 2 versus reduction in HCV RNA (log IU/mL) on Day 2 was performed. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
        <time_frame>Day 2</time_frame>
        <population>PK/PD Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>GSK2336805 40 mg, Genotype 1 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
          </group>
          <group group_id="O2">
            <title>GSK2336805 60 mg, Genotype 1 and Genotype 4 HCV</title>
            <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 ug once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation GSK2336805 Pre-dose Plasma Concentration on Day 2 Versus Reduction in HCV RNA on Day 2</title>
          <description>Correlation GSK2336805 pre-dose plasma concentration (ng/mL) on Day 2 versus reduction in HCV RNA (log IU/mL) on Day 2 was performed. As defined in the RAP for this protocol, correlations between GSK2336805 dose, and selected PK parameters and virological outcomes was analyzed only with graphical presentations to facilitate clinical interpretation and data summarization. These data were also provided in by-participant data listings. Therefore, no statistical summary tables are available.</description>
          <population>PK/PD Analysis Population</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs and non-SAEs were collected from the start of study treatment until the follow-up contact (up to 20 study weeks).</time_frame>
      <desc>SAEs and non-SAEs were collected in participants of the safety population, comprised of all participants who had received at least one dose of study medication (GSK2336805 or telaprevir).</desc>
      <group_list>
        <group group_id="E1">
          <title>GSK2336805 40 mg, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 40 mg orally (20 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG + RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on the eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken in 2 divided doses with food.</description>
        </group>
        <group group_id="E2">
          <title>GSK2336805 60 mg, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="E3">
          <title>Telaprevir, Genotype 1 HCV</title>
          <description>Participants with chronic G1 HCV infection received two telaprevir 375 mg tablets orally 3 times a day (7 to 9 hours apart) with food containing approximately 20 grams of fat in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
        <group group_id="E4">
          <title>GSK2336805 60 mg, Genotype 4 HCV</title>
          <description>Participants with chronic G4 HCV infection received GSK2336805 60 mg orally (30 mg x 2 tablets) once daily in the morning with food in combination with antiviral therapy (PEG+RIBA) for 12 weeks followed by PEG and RIBA alone for either 12 or 36 weeks based on eRVR achievement. PEG dose was 180 µg once weekly SC injection and the RIBA dose was 1000 mg orally (200 mg x 5 capsules) (if body weight was &lt;75 kg) or 1200 mg orally (200 mg x 6 capsules) (if body weight was &gt;=75 kg) taken orally in 2 divided doses with food.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eosinopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Monocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Drug withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injury associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gingival injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

